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Skeletal muscles are made up of bundles of muscle fibers formed from the fusion and 
differentiation of myoblasts (muscle cells) into myotubes (multi-nucleated myoblasts). 
The process of generating muscle, known as myogenesis, is tightly regulated by basic 
helix-loop-helix (bHLH) myogenic regulatory factors (MRFs), MyoD, Myf5, 
myogenin, and MRF4. MRFs control the transcriptional cascade of myogenic genes 
necessary for skeletal cell differentiation. The mechanisms involving MRFs in the 
development of the muscle fibers are well defined. However, several factors can 
negatively regulate myogenesis and the mechanisms by which they function in 
myogenesis are not clearly understood. Moreover, the mechanisms by which 
inhibitory factors contribute to myogenic defects and their roles in muscle disorders 
remain to be identified.  
 Sharp-1, a basic helix-loop-helix (bHLH) transcription factor, functions as a potent 
repressor of skeletal muscle differentiation and is dysregulated in muscle pathologies. 
However, the mechanisms by which Sharp-1 inhibits myogenic differentiation are 
unclear. In this work, I have identified a lysine methyltransferase G9a as a novel co-
factor that directly associates with Sharp-1, and is critical for Sharp-1-mediated 
repression of muscle differentiation. Similar to Sharp-1, G9a itself has an inhibitory 
role in skeletal myogenesis. In addition to mediating histone H3 lysine 9 di-
methylation repression marks on muscle promoters, G9a methylates MyoD, a key 
transcription factor required for muscle development, at lysine (K104). 
Overexpression of Sharp-1 in muscle precursor cells results in G9a-dependent histone 
modifications and MyoD methylation. siRNA-mediated knockdown of G9a or 
pharmacological blockage of its activity partially rescues the differentiation defects 
xii 
 
imposed by Sharp-1. These findings provide new insights into Sharp-1-dependent 
regulation of myogenesis and identify epigenetic mechanisms which could be targeted 
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1. Introduction    
The development of skeletal muscle tissue, also known as myogenesis, occurs 
embryonically. It involves the specification of cells into skeletal muscle lineage, 
migration of myoblasts (muscle precursor cells), followed by differentiation and 
fusion of these myoblasts into myotubes (multinucleated muscle cells). Myogenesis 
also occurs in the adult skeletal muscle in response to damage or injury. Myogenesis 
is governed by myogenic regulatory factors (MRFs) which tightly control the 
transcriptional regulatory networks in muscle cells. A deficiency of MRFs, or any 
abnormality in MRF function will affect proper skeletal muscle differentiation, 
leading to defects in embryonic muscle development and postnatal muscle 
regeneration. MRFs do not work alone but act together with multiple positively and 
negatively-acting regulatory proteins to control myogenesis. However, the 
mechanisms by which MRFs activity is modulated by its associated inhibitors are still 
poorly understood. Therefore, identification and characterization of proteins that 
inhibit MRF activity are required for in-depth understanding of the molecular 
mechanisms in muscle development and muscle disorders. A better understanding of 
how the myogenic regulatory network functions will facilitate the development of 
effective therapies for muscle-related disorders.   
 
1.1. Embryonic muscle development  
In vertebrates, the development of skeletal muscle tissues begins from the 
specification, migration, proliferation and differentiation of progenitor cells in somites 
present at the embryo stage. In the event of muscle differentiation in embryo, 
environmental signals and cues stimulate some of these progenitor cells to commit 
into different cell lineages such as skeletal muscle lineage and neural lineage.  
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The embryo which consists of totipotent cells form three germ layers of progenitor 
cells:  
1. Mesoderm are committed cells which will become the skeletal muscle, 
skeleton, dermis of skin, connective tissue, urogenital system, heart, blood 
(lymph cells), kidney, and spleen. 
2. Ectoderm are committed cells which will become the central nervous system, 
lens of the eye, cranial and sensory, ganglia and nerves, pigment cells, head 
connective tissues, epidermis, hair, and mammary glands. 
3. Endoderm are committed cells which will become the stomach, colon, liver, 
pancreas, urinary bladder, lining of the urethra, epithelial parts of trachea, 
lungs, the pharynx, thyroid, parathyroid, and intestines.  
The mesoderm layers eventually give rise to paraxial mesoderm, neural tube and 
notochord. Thereafter, paraxial mesoderm separates into blocks known as somites and 
these somites will subsequently proliferate and differentiate into four different cells 
including the sclerotome (that forms the vertebrae and rib cartilage), myotome (that 
forms the musculature of the back, ribs and limbs), dermatome (that forms the skin on 










Subsequent to myotome and dermatome formation, committed muscle progenitor 
cells, known as myoblasts, will eventually migrate and generate limb musculature. 
After migration into the limb bud, myoblasts begin to proliferate in the presence of 
growth factors (Christ et al., 1977, Christ and Brand-Saberi, 2002). Following the 
depletion of growth factors, myoblasts stop dividing and secrete fibronectin onto their 
extracellular matrix, resulting in terminal differentiation with fusion of myoblasts into 
myotubes (Olson, 1992). Myotubes mature into multinucleated myofibers and muscle 
tissues. The proliferation and differentiation of myogenic cells and fusion of cells to 
existing myofibers continue during postnatal growth of muscle.  
 
 
Figure 1.1. Development of muscle tissue (Taken from Scott F. Gilbert, 2010).  
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1.1.1. The myogenic regulatory network in embryonic muscle development - 
commitment of progenitor cells into myoblasts 
The commitment of the embryonic stem cells to become muscle lineage-committed 
myoblasts, is controlled by microenvironmental factors such as signalling proteins, 
growth factors and somite segmentation. Sonic Hedgehog (SHH), a protein secreted 
from notochord and ventral floor plate of the neural tube, acts as one of the positive 
microenvironmental factors. It induces the expression of myogenic transcription 
factors Paired box (Pax) genes in the segmental plate and dermomyotome of cells 
(Fan and Tessier-Lavigne, 1994, Johnson et al., 1994, Fan et al., 1995). Pax genes 
activate their downstream targets MyoD and Myf5 which trigger the myogenic 
pathway in the myotome (Munsterberg et al., 1995, Maroto et al., 1997) (Figure 1.2). 
At the same time, Wnt signalling proteins particularly Wnt-1, Wnt-3, and Wnt-4 
produced from surface ectoderm and neural tube also induce the expression of skeletal 
muscle-specific genes MyoD and myosin heavy chain (MHC) in cells (Münsterberg et 
al., 1995). The induction of Myf5 and MyoD are required for specification and 
commitment of mesodermal somitic cells to the myogenic lineage to become 
myoblasts.  
Besides positive regulatory signals, negative regulatory signals are present in the 
environment to inhibit and modulate the process of myogenesis. For example, growth 
factor such as bone morphogenetic proteins (BMP) is released from the lateral plate 
mesoderm to inhibit myogenesis. Concomitantly, the BMP antagonist Noggin is 
expressed within the dermomyotome to block BMP inhibitory activity. During the 
normal myogenic cell development, a low level of BMP signalling regulated by 
Noggin is necessary to control the ability of Pax3 cells to induce MyoD and Myf5 
expression (Reshef et al., 1998). Also, in the dorsal lip of the dermamyotome, MyoD 
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family inhibitor (Mdfi) is expressed in low amounts to modulate Myf5 expression 
during the specification of the skeletal muscle lineage (Kraut et al., 1998). Hence, 
positive and negative regulatory factors are essential and act together in a tightly 













1.1.2. The myogenic regulatory network in embryonic muscle development - 
differentiation of myoblasts into myotubes 
While the commitment of progenitor cells to myoblast cell fate is regulated by 
microenvironmental proteins, the proliferation and differentiation of myoblasts into 
myotubes (which form the muscle fibers) are regulated by MRFs. MRFs such as 
MyoD and Myf5 are upregulated by Pax proteins. At the same time that these proteins 
are upregulated, many mitogenic growth factors are induced. Mitogenic factors such 
as fibroblast growth factors and hepatocyte growth factors are secreted by the 
mesoderm cells to induce MEK/ERK signalling pathway. These signalling pathways 




are required for myoblast proliferation and migration during embryonic muscle 
development (Li et al., 2006). After several rounds of myoblast proliferation, MyoD 
and Myf5 upregulate the late MRFs such as myogenin and MRF4 which will in turn 
induce the expression of terminal differentiation genes such as troponin T, myosin 
heavy chain (MHC) and muscle creatine kinase (MCK). These muscle genes are 
required for terminal differentiation and fusion of myoblasts to form multinucleated 
myotubes. 
Hence, the process of differentiation towards the formation of skeletal muscle 
involves activation of positive regulating factors such as MRFs, growth factors and 
environmental signals. In addition, negative regulating factors are present to act in a 
concerted manner with positive regulating factors to regulate the determination, 
proliferation and terminal differentiation of embryonic muscle progenitors into 
muscle fibers. It is also important to note that where negative regulating factors are 
present in excess, they can affect proper functioning of MRFs, leading to abnormal 
skeletal muscle development.   
 
1.2. Adult skeletal muscle regeneration  
In the late stages of muscle development, while some myoblasts fuse to form skeletal 
muscle fibers, others develop into muscle-specific stem cells known as satellite cells. 
These satellite cells reside beneath the basal lamina of adult muscle fibers, are 
mitotically quiescent until local environmental stimuli appear. They are responsible 
for postnatal muscle growth and regeneration of adult myofibers after an injury 
(Schultz et al., 1978). In response to stimuli such as muscle injury, exercise and 
electrical stimulation, satellite cells emerge from the basal lamina, become activated 
to proliferate and express myogenic genes required for skeletal muscle differentiation. 
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Eventually, these cells differentiate and form new myofibers which fuse to existing 
muscle fibers to regenerate and repair damaged skeletal muscles.  
 
1.2.1. Adult skeletal muscle regeneration - activation of satellite cells  
Satellite cells in their quiescent and unproliferative state do not express MyoD but 
express Pax7 which is required for the maintenance of adult satellite cells and 
generation of committed progenitors (Seale et al., 2000, Relaix et al., 2006, Kuang et 
al., 2006). In response to environmental stress or muscle injury, muscle satellite cells 
will be activated and move out of the basal lamina. At the same time, inflammation 
occurs with fibroblastic growth factor (FGF), hepatocyte growth factor (HGF), 
insulin-like growth factor-I (IGF-I), cytokines and non-muscle mononucleated cells 
including neutrophils and macrophages are attracted to the site of injury. Other 
proteins such as leukemia inhibitory factors, IL-6, IL-15 and TNF-alpha also 
aggregate at the site of muscle damage. Together, these growth factors and proteins 
induce the satellite cells to exit its quiescent state and proliferate as myoblasts. 
Eventually, cells proliferate with proliferating cell nuclear antigen (PCNA, a maker 
for cell proliferation) expressed to promote the expression of MyoD in myoblasts. 
Although, MyoD is constitutively expressed in proliferating myoblasts, it is kept in a 
transcriptionally inactive form. MyoD can only be activated to execute the muscle 
differentiation program, upon the depletion of the growth factors and cessation of 
myoblast proliferation (Lassar et al., 1994).     
 
1.2.2. Adult skeletal muscle regeneration - terminal differentiation of myoblasts 
After several rounds of proliferation when the growth factors are depleted, Pax3 and 
Pax7 are downregulated. MyoD is activated to stimulate terminal differentiation of 
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myoblasts by upregulating myogenin and MRF4 expression. At the same time, MyoD 
induces expression of CDK inhibitor p21, which binds and inhibits cyclin-CDK2 or 
cyclin-CDK4 complexes. p21 promotes myoblast withdrawal from the cell cycle, a 
process that is necessary for myoblasts to express muscle-related genes and 
differentiate into myotubes (Guo et al., 1995, Hawke et al., 2003). After myoblasts 
exit the cell cycle, myogenin and MRF4 induce expression of terminal differentiation 
genes such as troponin T and MHC which are necessary to drive cellular 
differentiation and fusion of myoblasts. Troponin T and MHC are the major 
components of the contractile apparatus in muscle fibers. In addition to troponin T 
and MHC, structural and contractile proteins are produced to form new myofibers 
repairing the damaged muscle fibers within 4-5 days (Kelly and Zacks, 1969, Bischoff, 
1975, Konigsberg et al., 1975, Lipton and Schultz, 1979, Ontell and Kozeka, 1984, 
Megeney et al., 1996, Sabourin et al., 1999, Zammit et al., 2002, Relaix et al., 2005).  
While a population of myoblasts undergoes terminal differentiation, a fraction of 
myoblasts maintain Pax7, exits cell cycle and relocate to the basal lamina. These cells 
maintain a viable muscle satellite cells reservoir (Baroffio et al., 1996, Olguin et al., 
2004) so that they can continue to respond efficiently to repeated muscle injury (Luz 
et al., 2002, Sadeh et al., 1985). 
Similar to embryonic muscle development, myogenesis in adult muscle regeneration 
is also orchestrated through a transcriptional regulatory network controlled by MRFs. 
With coordinated transcriptional activities, muscle progenitors are activated to 
proliferate and subsequently undergo terminal differentiation. In the adult muscle 
regeneration, MRFs-associated negative regulatory proteins regulate muscle gene 
expression. Therefore, an imbalance between MRF and its negative regulatory 
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proteins in association can cause abnormal transcriptional activity and inefficient 
muscle regeneration during muscle injury.  
 
1.3. Transcriptional control of myogenic differentiation  
Skeletal muscle differentiation is controlled by two groups of myogenic transcription 
factors, the MRFs and the myocyte enhancer binding factor 2 (MEF2) proteins. MRFs 
such as MyoD, Myf5, Myogenin and Myf-6/MRF4/herculin are important basic-
helix-loop-helix (bHLH) positive transcriptional regulators critical for controlling the 
fate, migration, proliferation, differentiation, regeneration and survival of muscle cells. 
Generally, there are two separate processes in myogenesis: myoblast proliferation and 
differentiation. During myoblast proliferation, in the presence of growth factors, 
MyoD, Myf5 and E-proteins are expressed but both MyoD and Myf5 remain inactive. 
Upon deprivation of growth factors, muscle determination gene MyoD and Myf5 are 
activated to initiate cell differentiation. MyoD and Myf5 heterodimerize with 
ubiquitously expressed E-proteins (E12/E47/HEB) through their HLH domains. The 
resulting myogenic MyoD-E / Myf5-E heterodimers bind to E-box sites (CANNTG 
consensus sequence) present in promoters of many muscle-specific genes such as 
myogenin and MRF4 and transcriptionally induce gene expression (Lassar and 
Munsterberg, 1994, Arnold and Winter, 1998). Subsequently, expression of muscle 
differentiation genes myogenin and MRF4 trigger muscle terminal differentiation and 
stimulate synthesis of muscle-specific structural and contractile proteins such as MHC, 
α-actin, muscle creatine kinase, fast muscle-type and slow muscle-type of troponin T 
required for myofiber formation (Yutzey et al., 1990, Muscat et al., 1992, Li and 
Capetanaki, 1993, Ziober and Kramer, 1996, figure 1.3). However, in addition to 
MyoD and Myf5, studies have shown that MRF4, being normally described as a 
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differentiation gene, was also found to function a determination gene in vivo (Kassar-
Duchossoy  et al., 2004).  
The onset of terminal differentiation is preceded by cells exiting the mitotic cell cycle. 
Hence, besides inducing muscle gene expression for terminal differentiation, MyoD 
also binds to E-box sites and activates expression of the cell-cycle inhibitor p21 which 
mediates cell cycle exit (Figure 1.3) (Guo et al., 1995, Hawke et al., 2003). Induction 
of p21 leads to increased inhibition of cyclinD1-CDK4 and cyclinE-CDK2 activities 
which results in dephosphorylated retinoblastoma (Rb) binding to E2F and blocking 
transcription of cell cycle genes. Cell cycle exit is necessary to facilitate the 
expression of late skeletal muscle differentiation genes required for the myoblast 










During myogenic differentiation, MRFs also up-regulates MEF2 which binds MADS-
box promoter sites and activates transcription of muscle structural genes. MEF2 
factors are different from MRFs as they do not possess myogenic activity on their 
Figure 1.3. The myogenic differentiation pathway (Taken from the Konieczny lab 
website- www.bio.purdue.edu/people/faculty/konieczny/lab/overview.htm). 
 




own. However, MEF2 can enhance MRFs activity in the regulation of muscle gene 
expression (Molkentien et al., 1996, Black and Olson, 1998).  
Besides the example of MRFs and MEF2 activating transcription in a co-operative 
manner, it has been documented that most transcription factors often work in concert 
with transcription co-factors in modulating the activation of myogenic gene 
expression. The initiation of myogenesis by these MRFs is also accompanied by 
combined histone acetylation/deacetylation, histone methylation/demethylation of a 
particular histone lysine at regulatory regions or post-translational modifications of 
the transcription factors by phosphorylation or sumoylation (Eusebio et al., 2009).  
 
1.3.1. Deficiency of MRFs in muscle development 
Many in vivo knockout studies determined that MRFs play important functional roles 
during muscle development. Although mice lacking either the MyoD or Myf5 gene 
develop normal skeletal muscle, knockout of both MyoD and Myf5 inhibited 
myoblast formation and reduced muscle masses (Rudnicki et al., 1993). Mutation of 
Myogenin gene in mice resulted in reduced myofibers, fractures in ribs and death at 
birth (Hasty et al., 1993, Nabeshima et al., 1993). Mice lacking MRF4 displayed no 
overt defect in muscle development with only slight reduction of muscle specific 
genes (Olson et al., 1996). However, mice with double knockout of MyoD and MRF4, 
were phenotypically similar to myogenin knockout mice. In addition, these MyoD and 
MRF4 double mutants mice exhibited lethal deficiency of myofiber formation albeit 
the presence of the myogenin expression (Rawls et al., 1998). 
As described earlier, Pax3 and Pax7 function upstream of MRFs. Together, they are 
required for the determination and terminal differentiation of embryonic muscle 
progenitors. Some studies demonstrated that a homozygous Pax3 gene mutation 
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resulted in muscle weakness where myogenic progenitors failed to migrate from 
somites into the growing limbs and the developing tongue (Bober et al., 1994, 
Goulding et al., 1994, Tremblay et al., 1998). Similarly, other studies showed that 
Pax7 knockout newborn mouse has impaired regenerative capacity resulting in 
reduced muscle mass and shorter survival time (Mansouri et al., 1996, Oustanina et 
al., 2004). It has been shown that a double knockout of Pax3 and Pax7 in mice 
resulted in embryonic lethality and inhibition of myogenesis. In addition, improper 
trunk muscle development with inhibited MyoD expression was reported in Pax3 and 
Myf5 double mutant mice (Tajbakhsh et al., 1997). Hence, MRFs are critical muscle 
regulators in muscle development as any disruption in their expressions or activities 
can hinder proper muscle differentiation and lead to muscle disorder.  
 
1.4. Chromatin modifications in myogenesis  
Gene expression is regulated by transcription factors. However, gene expression is 
also epigenetically modulated, by post-translational modification of histone tails. 
Chromatin found in a repressive or transcriptionally inactive state can be switched to 
an in active state by several chromatin modifiers and remodeling proteins or vice 
versa. Chromatin modifiers also known as transcriptional co-factors do not bind 
directly to DNA but bind to the regulatory transcription factors instead to modulate 
gene transcription activity. When bound to the transcription factors, the transcription 
co-factors alter the chromatin structure to obstruct or enhance RNA polymerase from 
transcribing genes. Alteration of the chromatin structure takes place through 
epigenetic chemical modifications of the N-terminal tail regions of the core histones 
H2A, H2B, H3 and H4 (which are tightly bound to the DNA) by acetylation, 
methylation, phosphorylation, sumoylation and/or ubiquitylation (Kouzarides, 2007).  
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Similarly, in the myogenic regulatory network, while MRFs govern the ordered and 
specific expression of muscle genes required for terminal differentiation of myocytes 
into myofibers, their transcriptional activity can be altered by their associated 
transcriptional co-factors. There exist numerous transcriptional co-factors modifying 
the architecture of the chromatin at specific region and activate/repress the 
transcription of muscle differentiation gene.  
 
1.4.1. Chromatin modifications by histone deacetylases  
During the regulation of skeletal muscle gene expression, transcription factors MRFs 
and MEF2 do not work alone but are associated with histone acetylases (HATs) and 
histone deacetylases (HDACs) to activate or repress the myogenic genes (Dressel et 
al., 2001, Terranova et al., 2005). HATs and HDACs are enzymes that 
acetylate/deacetylate lysines on histones which can affect DNA-binding properties 
and gene expression. Histone lysine acetylation neutralizes the positive charge on the 
histones and decreases the histones ability to bind DNA. This permits DNA 
accessibility to the transcription factors and thus allows activation of gene 
transcription. Histone lysine deacetylation, on the other hand, increases histones 
affinity binding to the DNA and leads to chromatin condensation. A condensed 
chromatin structure prevents access of transcription factors to DNA and thus represses 
gene transcription. There are three classes of HDACs which are classified into three 
categories based on their homology to yeast proteins Rpd3p (class I), Hda1p (class II), 
and Sir2p (class III) (De Ruijter et al., 2003, North and Verdin, 2004). The 
deacetylase activity of class III HDAC is dependent on co-factor NAD and the 
activity of class I and II HDACs can be inhibited by Trichostatin A (TSA). These 
HDACs are implicated in the regulation of skeletal myogenesis where they can 
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physically associate with and restrain MyoD and MEF2 in a transcriptionally inactive 
state (Dressel et al., 2001, Terranova et al., 2005).  
In undifferentiated myoblasts, muscle differentiation genes are epigenetically marked 
for repression. MyoD is a dominant positive myogenic factor which is capable of 
binding to and initiating the expression of skeletal muscle genes (Salvatori et al., 
1995). Tapscott’s group showed that although MyoD is bound to muscle promoters in 
both differentiated myotubes and undifferentiated myoblasts. MyoD does not 
transcriptionally activate genes in myoblasts (Cao et al., 2010). In undifferentiated 
myoblasts, MyoD is expressed but kept in a deacetylated and transcriptionally 
inactive form by several epigenetic mechanisms (Mal et al., 2001). MyoD binds to 
HDAC1, via its bHLH domain and deacetylates histones on MyoD-target sites on 
promoters, resulting in a transcriptionally repressive chromatin state (Fulco et al., 
2003, Mal and Harter, 2003, Mal et al., 2001). HDACs have also been shown to have 
inhibitory roles in myogenesis. Overexpression of HDAC1 inhibits myoblast 
differentiation by deacetylating histones on promoters of late muscle genes such as 
MCK and MHC (Puri et al., 2001, Mal et al., 2001). In addition to deacetylating 
histones, HDAC1 deacetylates MyoD and kept it in a transcriptionally inactive form 
in undifferentiated myoblasts (Mal et al., 2001).  
With the onset of differentiation, myoblasts irreversibly withdraw from the cell cycle. 
Hence, in differentiating myoblasts, cell cycle genes are kept in a transcriptionally 
repressive state (Caretti et al., 2004, Zhang et al., 2002). The retinoblastoma protein 
(Rb) plays important roles in controlling cell cycle gene expression during myoblast 
differentiation (Huh et al., 2004). In undifferentiated myoblasts, HDAC1 is associated 
with MyoD but during the induction of myoblast differentiation, hypophosphorylated 
Rb competes with and replaces MyoD from the inhibitory MyoD-HDAC1 complex. 
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Thus, Rb-HDAC1 complex represses E2F target genes and silences S-phase genes 
whereas, MyoD is intact and activated to initiate myogenic transcription (Puri et al., 
2001, Blais and Dynlacht, 2007). Subsequently, as the myoblasts begin to 
differentiate, acetyltransferases p300/CBP associated factor (P/CAF) and p300 form a 
multimer complex with the dissociated MyoD which will bind to the myogenin 
promoter and activate expression of muscle genes (Puri et al., 1997a, Puri et al., 
1997b, Sartorelli et al., 1997, Sartorelli et al., 1999). While P/CAF acetylates MyoD 
at lysine K99, K102 and K104 required for MyoD transcriptional activity, p300 
acetylates histones H3 and H4 on the myogenin promoter (Puri et al., 1997, Sartorelli 
et al., 1999, Dilworth et al., 2004).  
However, these activities of co-activators can also be inhibited by transcriptional co-
repressors. The co-repressor HDAC3 associates with the acetyltransferases p300 and 
P/CAF to block myogenesis (Gregoire et al., 2006). In addition, HDAC4 and HDAC5 
can interact and block transcription factor MEF2 activity and subsequently repress 
transcription of both early and late muscle specific genes (Miska et al., 1999, Lu et al., 
2000, McKinsey et al., 2001, Wang et al., 1999, Lemercier et al., 2000). However, 
such myogenic repression mediated by the transcriptional co-repressors can be 
blocked by HDAC inhibitors.  
A class III HDAC-Sirt1/Sir2 forms a complex with MyoD and P/CAF and inhibited 
myogenesis. When NAD+/NADH+ ratio increases, Sirt1 blocks MyoD activity and 
induces histone deacetylation at muscle promoter, thus inhibiting differentiation. On 
the other hand, as the NAD+/NADH+ ratio decreases, Sirt1 activity reduces, allowing 





1.4.2. Chromatin modifications by methyltransferases  
Methyltransferases methylate lysine and arginine residues within histones or non-
histone proteins. Lysine residues can be mono-, di- or tri-methylated by several 
methyltransferases such as Suppressor of variegation 3-9 homologue 1/2 (Suv39h1/2), 
G9a-like protein (EHMT1/GLP), Polycomb group protein Enhancer of zeste 2 (Ezh2), 
SETDB1 / ESET and EHMT2/G9a. These methyltransferases can act either as co-
activators or co-repressors with the DNA binding transcription factors to activate or 
repress gene transcription, respectively (Jenuwein et al., 2001 Zhange and Reinberg, 
2001). For example, methylation of histone 3 lysine 9 (H3K9) is associated with 
inactive genes and tri-methylation of H3K9 is associated with pericentromeric 
heterochromatin and transcriptional repression. On the other hand, methylation of 
H3K4 and H3K17 have been generally associated with active genes and di-
methylation of H3K9 is associated with repression of transcription genes in 
euchromatin (Lee et al., 2005).  
In myoblasts, high levels of H3K9 methylation on the myogenin promoters, is 
associated with gene repression (Zhang et al., 2002, Mal and Harter, 2003). The 
histone methyltransferase Suv39h1 is recruited by MyoD to modify chromatin 
structure and block muscle gene expression. Suv39h1 tri-methylates H3K9 via its 
histone methyltransferase activity and inhibits myogenic differentiation (Mal, 2006). 
On the other hand, it has been suggested that Suv39h1 methylation activity is required 
during myogenic cell differentiation to repress cell-cycle genes. Their reports showed 
that reduced level of methyltransferase Suv39h1 was unable to express muscle genes 
and differentiate into myotubes (Ait-Si-Ali et al., 2004).  
In addition, the methyltransferase polycomb Ezh2 has been shown to be recruited by a 
non-muscle transcriptional regulator YY1 to add repressive chromatin marks on MCK 
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and MHCIIb genes promoters. Ezh2 di- and tri-methylates H3K27 through its HMKT 
activity thereby represses muscle gene expression (Caretti et al., 2004).  
Other methyltransferases such as Carm1/Prmt4 interacts with MEF2 proteins and di-
methylates H3R17 at MCK promoter, whereas Prmt5 associates with MyoD and di-
methylates H3R8 at both myogenin and MCK, dystrophin promoters (Chen et al., 
2002, Dacwag et al., 2009). Carm1/Prmt4 binding at late- myogenic promoters 
promotes binding of the Brg1 ATP-dependent chromatin-remodeling enzyme and 
subsequent chromatin remodeling at the promoter (Chen et al., 2002, Dacwag et al., 
2009). Hence, chromatin modification by methyltransferases is involved in the 
silencing myogenic gene expression and maintaining myoblasts in an undifferentiated 
state. 
 
1.4.3. Chromatin modifications by kinases and phosphatases  
It has been documented that kinase and phosphatase have roles in the regulation of 
myogenic differentiation. Studies have shown that kinases cdk1 and cdk2 
phosphorylate MyoD and restrict its activity. Phosphorylated MyoD is targeted for 
ubiquitination and degradation (Song et al., 1998). MyoD is highly phosphorylated by 
cdk1 and cdk2 in proliferating myoblasts and is dephosphorylated in differentiating 
myoblasts (Kitzmann et al., 1999).  
Protein kinase C (PKC), activated in the presence of fibroblast growth factor, 
phosphorylates myogenin and blocks its DNA binding activity (Li et al., 2005). 
Protein kinase A (PKA), on the other hand, has been shown to phosphorylate and 
inhibit both Myf5 and MyoD activities (Winter et al., 1993). Similarly, cyclin-
dependent kinase 4 (cdk4) binds directly to MyoD and disrupts its DNA binding and 
its transcriptional activity (Zhang et al., 1999a). 
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Other studies have indicated that mitogen-activated protein kinase p38-α is required to 
phosphorylate E47 at Serine140 to promote heterodimerization of E47/MyoD and 
transcription of muscle genes. The data show that when E47 is unphosphorylated, it 
fails to bind MyoD. Thus, the transcription factor MyoD alone cannot bind to 
regulatory sites and initiate transcription of muscle genes (Luis et al., 2005). 
Conversely, the isoform p38-γ phosphorylates Serine199 and Serine200 on the 
carboxy terminus of MyoD which enhances its interaction with transcriptional 
repressor histone methyltransferase Suv39h1 to inhibit myogenesis (Lassar, 2009). 
Hence, kinases and phosphatases have both activating and inhibitory functions in 
regulating MRF activity.  
Other chromatin modifiers include the ATPase-dependent SWI/SNF remodeling 
complexes which are recruited to muscle promoters to activate muscle differentiation 
(Simone et al., 2004, Albini and Puri 2010). During differentiation, p38 alpha/beta 
kinases are activated to promote SWI/SNF recruitment onto the chromatin of muscle 
genes to induce muscle differentiation.  
Thus, MRFs and epigenetic regulators play important roles in modulating the activity 
of MRFs and myogenic differentiation. There is a network of functional interactions 
between transcription factors and chromatin-modifying complexes that regulate the 
muscle gene-specific chromatin conformation during the transition of myoblasts to 
myotubes.  
 
1.5. Regulation of myogenesis by repressors  
A number of proteins which negatively regulate myogenesis have been identified. For 
example, bFGF (basic fibroblast growth factor), TGF-β (transforming growth factor), 
Myostatin, and Notch signalling have been shown to inhibit proliferation of muscle 
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stem cell and to block recruitment and fusion of myoblasts into myofibers (Kopan et 
al., 1994, Nofziger et al., 1999, Langley et al., 2002, Yoshiko et al., 2002). Activation 
of Notch1 leads to satellite cell proliferation but prevents differentiation (Conboy and 
Rando, 2002). Various other oncogenes such as c-myc, N-ras, and Ha-ras also inhibit 
muscle differentiation in vitro (Olson et al., 1987). These proteins or growth-
promoting factors negatively regulate the transcriptional activity of MRFs in 
myogenic differentiation.  
Besides signalling proteins, HLH transcriptional repressors have been shown to block 
muscle gene expression. MRFs bind to the E-box regulatory region to activate 
transcription of muscle genes, but at the same time, negative regulators can compete 
for the same regulatory region to block MRFs from binding and triggering muscle 
gene transcription. Also, the repressors can bind directly to the MRF to suppress its 
transcriptional activity (Lemercier et al., 1998, Rawls et al., 1998, Azmi et al., 2003). 
One example is the inhibitor of DNA binding/differentiation (Id) family protein which 
is a HLH protein but lacks a basic DNA-binding domain. Id, through its HLH domain, 
binds to MRFs and prevents it from binding to the E-box (Benezra et al., 1990). It 
also heterodimerize with E-proteins and prevents the formation of functional MRF-E-
protein heterodimer to bind E-box, leading to a repression of myogenic genes and 
inhibited myoblasts differentiation. Other bHLH transcriptional repressors of muscle 
gene include Twist, Mist1, MyoR (myogenic repressor), Hes1 (Hairy and Enhancer of 
Split), Hey1 (Hairy/ enhancer-of-split-related with YRPW motif 1), Hesr (hairy and 
enhancer of split related HESR family) and Sharp-1 (Enhancer of split and Hairy-
related protein 1). Twist interacts with the basic domain of MyoD and represses 
MyoD transactivation. Similar to Id, Twist sequesters E-proteins, inhibits MEF2 
activation and blocks P/CAF and p300 histone acetylase activity (Spicer et al., 1996). 
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In myogenesis, both the transcriptional co-activators p300 and P/CAF are necessary 
for MyoD to activate skeletal muscle program. Akin to the other repressor’s 
mechanism in attenuating MyoD transcriptional activity, Mist1 heterodimerizes with 
E-protein, occupies E-box sites and blocks muscle gene expression or heterodimerizes 
with MyoD resulting in inactive MyoD (Lemercier et al., 1998). Other inactive forms 
of MyoD heterodimers include Hes1/MyoD (Sasai et al., 1992) and Sharp-1/MyoD 
(Azmi et al., 2004), negatively regulate myogenesis. These repressors are also known 
to block myogenesis, however, the details regarding the molecular mechanism, 
biological pathway of the repressors-mediated inhibition of MRFs remains to be 
determined.   
Among these repressors, our laboratory is interested and focused on the role of Sharp-
1 in regulating cellular proliferation and differentiation. Sharp-1 has been identified as 
a transcriptional repressor in both myogenic differentiation and adipocyte 
differentiation (Azmi et al., 2004, Gulbagci et al., 2009). The molecular mechanisms 
underlying Sharp-1-mediated repression of myoblast differentiation remain unclear 
(Azmi et al., 2004).  
 
1.6. The transcriptional repressor Sharp-1  
Mus musculus Sharp-1 (Enhancer-of-Split and Hairy-related protein 1), also known as 
homo sapiens DEC2 (differentiated embryo chondrocyte protein 2), BHLHE41 or 
bHLHB3, is a 410 amino acid transcription factor which is involved in the control of 
proliferation and differentiation of several cell types including epithelial cells, nerve 
cells and fibroblasts (Sato et al., 2008, Liu et al., 2009, Cho et al., 2009, Garriga-
Canut et al., 2001, Gulbagci et al., 2008, Azmi et al., 2004).  
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The mouse SHARP-1 gene maps to chromosome 6 G2-G3 and the human homologue 
DEC2 gene maps to chromosome 12p11.23-p12.1 (Fujimoto et al., 2001). Sharp-1 
contains a bHLH domain at the N-terminus, an orange domain and an alanine / 
glycine-rich domain at the C-terminus. Its basic region contains an Arg 13 residue 
which is important for DNA-binding to the consensus sequence CACGTG. Its 
adjacent HLH region mediates homo- or hetero-dimerization with other HLH proteins.  
Phylogenetics analyses revealed that Sharp-1 belongs to the bHLH transcription 
factors (Hey, Hes, Stra13/DEC1) family (figure 1.4) that regulate many physiological 
processes such as cellular differentiation, cell cycle arrest and apoptosis (Sun et al., 
2007). Sequence alignment shows that it shares highest sequence homology (89%, 
366 out of 410 amino acid conserved) to Sharp-2/Stra13 (stimulated by retinoic acid 
13 homolog) /DEC1 with 95% amino acid identity in their bHLH domain. The bHLH 
region of Sharp-1 is structurally similar (40%) to that of Hes and Hey proteins.  
Hes/Hey proteins, through their WRPW or YRPW domain, recruit co-repressor 
Groucho to repress transcription and suppress neurogenesis. Although Sharp-1 
belongs to the bHLH family, it represses gene transcription differently from other 
members of bHLH transcription factors as its C-terminus lacks the WRPW or YRPW 




























Sharp-1 expression is regulated by various extracellular stimuli such as growth factors, 
serum starvation, hypoxia and cytokines (Yamada and Miyamoto, 2005). Sharp-1, is 
expressed in various tissues, and plays an important role in multiple signalling 
pathways that impact many biological processes including development, cell 
differentiation, cell growth, cell death, circadian rhythms. Its mRNA is expressed at 
high levels in the heart, skeletal muscle, and brain and at low levels in the lung, 
placenta, pancreas and kidney and in both embryonic and adult tissues (Shen et al., 
 
Figure 1.4. The domain structure of Sharp-1 (Taken from Sun et al., 2007). 
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1997, Fujimoto et al., 2001, Azmi et al., 2002). Unlike other bHLH protein, Sharp-1 
is expressed in post-natal neurons but not in neuronal progenitor cells or early 
differentiating neurons, suggesting that it has a role in terminal neuronal 
differentiation (Rossner et al., 1997).  
 
1.6.1. Transcriptional repression by Sharp-1  
In most cells, Sharp-1 mainly functions as a transcriptional repressor which silences 
gene expression. Several mechanisms are involved in Sharp-1-dependent 
transcriptional repression. The first mechanism is dependent on binding of Sharp-1 
homodimers to class B E-box elements (CACGTG), resulting in repression of 
transcription. For instance, Sharp-1 binds directly to E box elements in the Stra13 
promoter and inhibits its expression. Stra13 shares the highest sequence homology 
with Sharp-1, functions as a transcriptional repressor and is involved in the control of 
differentiation of several cell lineages during mouse development. In addition, Sharp-
1 also sequesters the transcription factor Sp1 and impedes its transcription activity on 
Stra13 promoter (Kawamoto et al., 2004, Sun and Taneja, 2000, Azmi et al., 2003). A 
second mechanism is by interaction with other transcription factors blocking their 
activity and resulting in repression of gene expression (Azmi et al., 2003, Yamada 
and Miyamoto 2005). Previous studies from our laboratory have shown that Sharp-1 
negatively regulates adipose cell differentiation. Sharp-1 attenuates the transcriptional 
activity of both CCAAT/enhancer binding protein α and β (C/EBPα and C/EBPβ) 
required for the development of white adipose tissues. This reduced transcriptional 
activity leads to inhibition of C/EBPα and peroxisome proliferator-activated receptor 
γ (PPARγ) genes expression and adipocytic differentiation (Gulbagci et al., 2009). 
Apart from inhibiting adipogenesis, Sharp-1 negatively regulates genes required for 
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myogenic differentiation. The inhibitory activity of Sharp-1 occurs through sequesting 
of MyoD and E-protein, thus resulting in a block of MyoD transcriptional activity 
(Azmi et al., 2004).   
Sharp-1 has been reported to recruit HDAC1 through its C-terminus that may be 
important for repression of specific target genes (Garriga-Canut et al., 2001). For 
instance, Sharp-1 represses muscarinic receptor gene and its repressive effect can be 
overcome with a histone deacetylase inhibitor Trichostatin A (Garriga-Canut et al., 
2001). Similarly DEC2 (Sharp-1) represses transactivation of retinoid X receptor 
(RXR) and the retinoid X receptor-liver X receptor (RXR-LXR) heterodimers, in a 
HDAC-dependent mechanism. Both RXR and LXR are transcription factors required 
for cell growth and differentiation in sebocyte and myeloid cells (Cho et al., 2009, 
Kim et al., 2000).  
Sharp-1/DEC2 plays a role in the regulation of circadian rhythms. Brain and muscle 
Arnt-like protein-1 (BMAL1) is a transcription factor known to regulate circadian 
rhythm. Both Sharp-1/DEC2 and Stra13/DEC1 repress the transcriptional activity of 
BMAL1 through direct protein-protein interaction with BMAL1 or competition for 
binding to the E-box elements (Hamaguchi et al., 2004, Honma et al., 2002, 
Kawamoto et al., 2004, Sato et al., 2004) 
It has also been shown that Sharp-1 functions as a transcriptional repressor in the 
paracrine regulation of ductal growth and differentiation. Sharp-1 binds and hinders 
hypoxia-inducible factor, a transcription factor from binding to the promoter, resulting 
in downregulation of vascular endothelial growth factor (VEGF) expression (Sato et 
al., 2008). 
Surprisingly, besides being a repressor, a recent study demonstrated that Sharp-1 can 
perform dual functions as a repressor or activator of clock gene expression depending 
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on the nature of E-box binding complexes in different tissues. Sharp-1 serves as a 
repressor of E-box-mediated transcription in the cortex and liver. On the contrary, 
through rapid delays of the light-dark cycle (experimental jet lag) and light-pulse 
experiments, it was shown that Sharp-1 induces expression of light-responsive genes 
c-Fos, c-Jun and Per1 in the suprachiasmatic nucleus (Rossner et al., 2008).  
 
1.6.2. Role of Sharp-1 in myogenesis  
Sharp-1 mRNA is expressed in proliferating C2C12 myoblast cells. Its expression 
declines during myogenic differentiation which suggests that Sharp-1 may have a role 
in keeping myoblasts in an undifferentiated proliferative state. Consistent with these 
studies, overexpression of Sharp-1 in C2C12 myoblast cells has been shown to inhibit 
myoblast differentiation into myotubes. Moreover, using myogenic conversion assays 
in C3H10T½ mouse fibroblast cells, Sharp-1 was found to inhibit MyoD-dependent 
myogenic differentiation and expression of myogenin, MEF2C and myosin heavy 
chain during differentiation (Azmi et al., 2004). 
This inhibitory effect of Sharp-1 is in part due to inhibition of the transcriptional 
activity of E protein-MyoD complexes. Sharp-1 heterodimerizes with transcription 
factors MyoD and E-proteins, through their HLH domain and prevents the formation 
of MyoD/E47 dimers and thus blocks myogenic differentiation (Garriga-Canut et al., 
2001, Azmi et al., 2004, Fujimoto et al., 2007). Importantly, even though Sharp-1 
represses transcription through its bHLH domain, a tethered MyoD-E47 dimer is still 
unable to completely overcome Sharp-1-mediated repression. This suggests that 
Sharp-1 has more than one mechanism in inhibiting myogenic differentiation (Azmi 
et al., 2004).  Hence, Sharp-1 has an inhibitory role in myogenic differentiation and 
its bHLH domain is not the only mechanism in blocking muscle gene expression. In 
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the neurons, Sharp-1 abrogates gene expression in a HDAC-dependant manner 
(Garriga-Canut et al., 2001). Interestingly and in contrast, in muscle cells, HDAC1 is 
not involved in Sharp-1-mediated repression of MyoD activity (Fujimoto et al., 2007).  
Previous studies from our laboratory have shown that Sharp-1 recruits transcriptional 
co-factors HDAC1 and G9a onto C/EBPα and PPARγ promoters during the inhibition 
of adipocyte differentiation (Gulbagci et al., 2009). This raised the possibility that 
Sharp-1 may recruit G9a to regulate muscle gene expression. This study therefore 
examines the role of methyltransferase G9a and its recruitment by Sharp-1 in 
myogenesis.   
 
1.7. The methyltransferase G9a  
The methyltransferase G9a, also known as Euchromatic histone lysine N-
methyltransferase 2 (Ehmt2), Bat8, KMT1C and NG36, belongs to the histone-lysine 
methyltransferase family which includes Suv39h1, SET9 and Ezh2. The Homo 
sapiens G9a is located on chromosome 6 p21.31 (Brown et al., 2001). There are two 
isoforms, a long isoform with 1210 amino acids and a short isoform with 1001 amino 
acids. The Mus musculus G9a is located on chromosome 17. The long isoform 
consists of 1263 amino acids and the short isoform consists of 1172 amino acids. 
Ubiquitously expressed, G9a has been suggested to have 2 nuclear localisation signals 
in the Gly-Arg rich repeats and is localised exclusively in the nucleus. The carboxyl 
terminus of G9a consists of 6 ankyrin repeats that serve to interact with other proteins 
(Davis et al., 1991) and a conserved catalytic SET domain (about 130 amino acids) 
flanked by 2 cysteine-rich regions. The amino end of G9a has very little similarity 
with any conserved protein domain (Figure 1.5). It is a histone lysine 
methyltransferase (HKMT) enzyme that methylates specific lysine residues within the 
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histone tails. As described earlier, methylation of lysine on histones is usually 
associated with transcriptional repression. G9a preferentially mono- or di-methylates 
H3K9 and less efficiently H3K27. G9a recognizes Arg-Lys (RK) sequence and that 































human         LYLSVKQGELQKVILMLLDNLDPNFQSDQQSKRTPLHAAAQKGSVEICHVLLQAGAN--- 
Sus           LYLSVKQGELQKVILMLLDNLDPNFQSDQQSKRTPLHAAAQKGSVEICHVLLQAGAN--- 
Mus           LYLSVKQGELQKVILMLLDNLDPNFQSDQQSKRTPLHAAAQKGSVEICHVLLQAGAN--- 
Rat           LYLSVKQGELQKVILMLLDNLDPNFQSDQQSKRTPLHAAAQKGSVEICHVLLQAGAN--- 
Danio         LYPAAKQGEAQRVLLMLMEGMDPSYQSDSQNRRCALHAAAQRGLLEICYLLVQAGAK--- 
Drosophila    MYYAVQNDDLERVAEILAADFNVLTPIREYLNGTCLHLVAHSGTLQMAYLLLCKGASSPD 
         
 
human         -INAVDKQQRTPLMEAVVNNHLEVARYMVQRGGCVYSKEEDGSTCLHHAAKIGNLEMVSL 
Sus           -INAVDKQQRTPLMEAVVNNHLEVARYMVQRGGCVYSKEEDGSTCLHHAAKIGNLEMVSL 
Mus           -INAVDKQQRTPLMEAVVNNHLEVARYMVQLGGCVYSKEEDGSTCLHHAAKIGNLEMVSL 
Rat           -INAVDKQQRTPLMEAVVNNHLEVARYMVQLGGCVYSKEEDGSTCLHHAAKIGNLEMVSL 
Danio         -VDAQDKSLRTPLLEAIVNNHVDVVKYLIQSGACVYHAEDDGSTGLHHAAKLGNLEVVML 
Drosophila    FVNIVDYELRTALMCAVMNEKCDMLNLFLQCGADVAIKGPDGKTSLHIAAQLGNLEATQL 
 
 
human         LLSTG---------QVDVNAQDSGGWTPIIWAAEHKHIEVIRMLLTRGADVTLTDNEENI 
Sus           LLSTG---------QVDVNAQDSGGWTPIIWAAEHKHIEVIRMLLTRGADVTLTDNEENI 
Mus           LLSTG---------QVDVNAQDSGGWTPIIWAAEHKHIDVIRMLLTRGADVTLTDNEENI 
Rat           LLSTG---------QVDVNAQDSGGWTPIIWAAEHKHIDVIRMLLTRGADVTLTDNEENI 
Danio         LLSTG---------QVDINAQDSGGWTPVIWAAEHRHIEVIRALLNRGADVTLRDKEMNV 
Drosophila    IVDSYRTSRNITSFLSFIDAQDEGGWTAMVWAAELGHTDIVSFLLNQDADPNICDNDNNT 
 
 
human         CLHWASFTGS-AAIAEVLLNARCDLHAVNYHGDTPLHIAARESYHDCVLLFLSRGANPEL 
Sus           CLHWASFTGS-AAIAEVLLNARCDLHAVNYHGDTPLHIAARESYHDCVLLFLSRGANPEL 
Mus           CLHWASFTGS-AAIAEVLLNAQCDLHAVNYHGDTPLHIAARESYHDCVLLFLSRGANPEL 
Rat           CLHWASFTGS-AAIAEVLLNAQCDLHAVNYHGDTPLHIAARESYHDCVLLFLSRGANPEL 
Danio         CLHWASFAGS-AEIAELVLNAGCPLSSVNVHGDTPLHISAREGYSDCVTLFLSRGADIDI 
Drosophila    VLHWSTLHNDGLDTITVLLQSGADCNVQNVEGDTPLHIACRHSVTRMCIALIANGADLMI 
 
 
human         RNKEGDTAWDLTPERSDVWFALQLNRKLRLGVGNRAIRTEKIICRDVARGYENVPIPCVN 
Sus           RNKEGDTAWDLTPERSDVWFALQLNRKLRLGVGNRAIRTEKIICRDVARGYENVPIPCVN 
Mus           RNKEGDTAWDLTPERSDVWFALQLNRKLRLGVGNRAVRTEKIICRDVARGYENVPIPCVN 
Rat           RNKEGDTAWDLTPERSDVWFALQLNRKLRLGVGNRAVRTEKIICRDVARGYENVPIPCVN 
Danio         VNKEGDTPLSLARGETPVWVALQINRKLRRGIANRIVRTERIICSDVAQGYENVPIPCVN 
Drosophila    KNKAEQLPFDCIPNE-ESECGRTVGFNMQMRSFRPLGLRTFVVCADASNGREARPIQVVR 
 
 
human         ----------GVDGEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQ 
Sus           ----------GVDSEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQ 
Mus           ----------GVDGEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQ 
Rat           ----------GVDGEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQ 
Danio         ----------GVDDEGCPSDYKYIAENCETSAMNIDRNITHLQHCSCTDDCSSSNCLCGQ 
Drosophila    NELAMSENEDEADSLMWPDFRYVTQCIIQQNSVQIDRRVSQMRICSCLDSCSSDRCQCNG 
 
 
human         LSIRRWYDKDGRLLQEFNKIEPPLIFECNQACSCWRN-CKNRVVQSGIKVRLQLYRTAKM 
Sus           LSIRCWYDKDGRLLQEFNKIEPPLIFECNQACSCWRN-CKNRVVQSGIKVRLQLYRTAKM 
Mus           LSIRCWYDKDGRLLQEFNKIEPPLIFECNQACSCWRS-CKNRVVQSGIKVRLQLYRTAKM 
Rat           LSIRCWYDKDGRLLQEFNKIEPPLIFECNQACSCWRS-CKNRVVQSGIKVRLQLYRTAKM 
Danio         LSIRCWYDKDHRLLQEFNKIEPPLIFECNMACSCHKT-CKNRVVQAGIKVRLQLYRTEKM 
Drosophila    ASSQNWYTAESRLNADFNYEDPAVIFECNDVCGCNQLSCKNRVVQNGTRTPLQIVECEDQ 
                
 
human         G--WGVRALQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGN 
Sus           G--WGVRALQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGN 
Mus           G--WGVRALQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGN 
Rat           G--WGVRALQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGN 
Danio         G--WGVRALQDIPQGSFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGN 
Drosophila    AKGWGVRALANVPKGTFVGSYTGEILTAMEADRRTDDSYYFDLDNG----HCIDANYYGN 
               
 
human         ISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIRTGEELGFDYGDRFWDIKSKYF 
Sus           ISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIRTGEELGFDYGDRFWDIKSKYF 
Mus           ISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIRTGEELGFDYGDRFWDIKSKYF 
Rat           ISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIRTGEELGFDYGDRFWDIKSKYF 
Danio         ISRFINHLCDPNIIPVRVFMLHQDLRFPRIAFFSSRDIFTGQELGFDYGDRFWDIKSKYF 
Drosophila    VTRFFNHSCEPNVLPVRVFYEHQDYRFPKIAFFSCRDIDAGEEICFDYGEKFWRVEHRSC 
 
 
 human         T-CQCGSEKCKHSAEAIALEQSRLARLDPHPELLPELGSLPPVNT--- 
 Sus           T-CQCGSEKCKHSAEAIALEQSRLARLDPHPELLPELSSLPPVNP--- 
 Mus           T-CQCGSEKCKHSAEAIALEQSRLARLDPHPELLPDLSSLPPINT--- 
 Rat           T-CQCGSEKCKHSAEAIALEQSRLARLDPHPELLPDLSSLPPINT--- 
 Danio         T-CQCGSEKCKHSAEAIALEQSRLARLEVCVEPDTALSLIGHS----- 












Figure 1.5. Protein sequence alignment of G9a in different species 
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G9a-mediated methylation is not restricted to histones. G9a has been shown to be 
capable of methylating non-histone proteins at the consensus Argine-Lysine (RK) 
amino acid such as CDYL1 (chromodomain Y-like protein), WIZ (widely interspaced 
zinc finger motifs protein), C/EBP, Reptin, ACINUS, CENP-A, CENP-B, CENP-C, 
TRF1 TRF2 and  p53 and itself (Ueda et al., 2006, Chin et al., 2007, Rathert et al., 






Other methyltransferases such as Ezh2 and Suv39h1 have been shown to inhibit 
myogenic differentiation. During the inhibition of myogenic differentiation, 
overexpression of Ezh2 increased H3K27 di- and tri-methylation levels at the MHC 
(late muscle marker) promoter (Caretti et al., 2004) whereas overexpression of 
Suv39h1 increased H3K9 tri-methylation level at the myogenin promoter (Mal et al., 
2006). An increase in histone methylation is associated with repression in the gene 
expression (Jenuwein and Allis, 2001, Li et al., 2007). 
Figure 1.6. G9a methylates non-histone proteins. (Modified from Collins et al., 2010).  
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G9a is a major H3K9 methyltransferase for euchromatin and is responsible for the 
transcriptional repression of many euchromatic genes (Gyory et al., 2004, Nishio and 
Walsh, 2004, Roopra et al., 2004, Duan et al., 2005, Tachibana et al., 2002, Kim et al., 
2008).  
 
1.7.1. Functions of G9a 
The methyltransferase G9a is important in the methylation of euchromatic H3K9 and 
plays an important role in cellular differentiation, development and cell-cycle 
progression. The knockout of G9a in mice results in a decrease in global H3K9me1 
and H3K9me2 levels. Moreover, mouse embryos deficient of G9a suffers from severe 
growth retardation and early lethality (Tachibana et al., 2002) 
Previous studies found that methyltransferase G9a functions as a co-repressor which 
is recruited to several specific genes by associating with transcriptional repressors and 
co-repressors such as CDP/cut, Blimp-1/PRDI-BF1, and REST/NRSF.  
A report showed that in many diverse cellular and viral genes, a transcriptional factor, 
CCAAT displacement protein/cut homolog (CDP/cut) involves G9a in regulating 
cellular processes, including differentiation, development, and proliferation. CDP/cut 
functions as a transcriptional repressor, recruits histone lysine methyltransferase G9a 
activity to repress transcription of p21 and inhibit cell cycle exit (Nishio and Walsh, 
2004). Another similar report showed that UHRF1 recruits G9a to inhibit p21 
promoter activity in regulating cellular proliferation (Kim et al., 2008). Similarly, it 
has been shown that the transcriptional repressor neuron restrictive silencing factor 
(NRSF/REST) can also recruit histone methyltransferase G9a to silence NRSF target 
genes in nonneuronal cells (Roopra et al., 2004). 
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A DNA-binding protein PRDI-BF1, which is important in silencing multiple genes to 
drive terminal stage of B cell differentiation, has also been reported to associate with 
G9a. It recruits histone methyltransferase G9a to promoters to repress transcription of 
interferon-β (IFNB1) which is required for terminal stage of B cell differentiation. 
IFNBI gene silencing is also mediated through G9a HKMT catalytic activity (Gyory 
et al., 2004).  
 
1.8. Muscular dystrophy  
Muscular dystrophies are a group of heterogeneous genetic disorders that lead to 
degeneration and wasting of skeletal muscles. DMD, caused by mutations in the 
dystrophin gene (Koenig et al., 1987), is the most prevalent muscular dystrophy that 
affects 1:3500 males. DMD is characterized by progressive skeletal muscle 
degeneration and the subsequent replacement of muscles by fibrotic and fat tissue. 
Patients typically are wheelchair bound in their early teens, and die in the early 
twenties due to respiratory and cardiac failure. The mdx mice lacking dystrophin have 
been widely studied as a mouse model for DMD and for exploring therapeutic 
strategies. Muscle degeneration and necrosis in mdx mice occurs between 3-8 weeks 
of age, and subsides in limb muscles thereafter, with the exception of the diaphragm 
that displays progressive degenerative changes and fibrosis. Despite intensive 
research, the mechanisms underlying muscle degeneration in DMD are largely 
unclear but a failure of myogenic satellite cells to maintain muscle regeneration 




1.8.1. Current therapy for muscular dystrophy 
Muscular dystrophy is currently a major and unsolved public health problem. To date, 
although many kinds of studies including gene transfer strategies have been 
implemented, but no effective treatment for muscular dystrophy has been established. 
There is no known cure for muscular dystrophy and treatment is generally aimed at 
controlling the onset of symptoms to maximize the quality of life. Presently, only 
physical therapy is able to help patients maintain their muscle strength and mobile 
function. Besides cell-based therapies, alternative would be the use of orthopedic 
appliances, such as braces and wheelchairs, which improve patients’ mobility and 
self-care ability. In some cases, patients receive surgery on the spine or legs to 
improve their muscle function.  
The studies on various strategies for treatment of muscular diseases are still in 
progress. Currently, these strategies are categorized into two approaches -- Exogenous 
delivery and endogenous activation : 
- The first approach relies on exogenous tools (gene, cell therapy) to improve 
muscle regeneration. Due to the availability and remarkable capacity of 
satellite cells to regenerate in damaged muscle, satellite cells and their 
descendent myoblasts have been used for stem cell-based therapies to treat 
muscular dystrophy. In stem cell-based therapy, myoblast transfer therapy has 
been proposed as a treatment for DMD, in which muscle precursor cells are 
transplanted directly into muscle fibers to replace damaged muscle tissues. 
However, donor myoblasts are less capable of cell migration and fuse poorly 
with recipient myotubes. Thus, the existing satellite cell-based therapy is still 
not an effective cure.  
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- The second approach consists of activating endogenous cells to stimulate 
myogenic factors and achieve muscle hypertrophy. Small molecule inhibitors 
have been identified and they play an important role in stem cell biology and 
regenerative medicine. 
For example, some significant studies have shown that histone deacetylases (HDACs) 
inhibit the activities of MRFs such as MyoD and MEF2, leading to impairment of 
myogenic differentiation in muscle. Currently, several HDAC inhibitors have been 
developed and tested in clinical trials testing on the therapeutical potential in 
treatment of muscle and heart disease (Nebbioso et al., 2009). Rescue work has been 
carried out to prove that calcium/calmodulin-dependent protein kinase (CaMK) and 
calcineurin signalling can overcome the HDAC-mediated deacetylation and 
repression on MEF2 transcriptional activity. Treatment with a HDAC inhibitor such 
as Trichostatin A (TSA) induces follistatin expression which promotes 
hypernucleated myotubes and enhances expression of regeneration markers following 
muscle injury (Lezzi et al., 2004). In molecular study, follistatin has been shown to be 
able to induce satellite cells to exit from quiescence during myogenesis (Le Grand and 
Rudnicki 2007). Similarly, spinal muscular atrophy (SMA) mouse treated with other 
HDAC inhibitors such as valproic acid and phenylbutyrate also displayed enhanced 
differentiation of satellite cells. These treated mice exhibited better motor function, 
larger motor-evoked potentials, less degeneration of spinal motor neurons, less muscle 
atrophy, and better neuromuscular junction innervation than non-treated SMA mice 
(Mercuri et al., 2004, Brahe et al., 2005, Tsai et al., 2008a). In fact, these small 
molecules such as HDAC inhibitors and DNA methyltransferase inhibitors have 
already been proven useful in the treatment of cancer and may serve as potential 
pharmacological compounds for therapeutic treatment of muscular dystrophy. 
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However, the use of HDAC inhibitor as a therapeutic treatment for muscular 
dystrophy is closely monitored with caution. The effectiveness, toxicity and 
consequences of these drugs in human cells are not yet fully known and have to be 
assessed carefully.  
Ironically, many approaches towards treatment for muscle disorders are not possible. 
Currently, understanding of the nature and fundamental cause of the disease is poor. 
In addition, the study of cellular and molecular events in muscle growth and 
regeneration is insufficient. The molecular mechanisms underlying the activation and 
function of the myogenic stem cells remains unclear and there is insufficient 
knowledge on the mechanisms underlying the inhibitors–mediated repression of MRF 
gene transcription in muscular disease.  
Regenerative medicine requires a thorough understanding of the myogenic regulatory 
network controlling skeletal muscle proliferation, self-renewal and myogenic 
differentiation. Hence, there is a need for continuous research studies on gene 
regulation in muscle development and to identify repressor proteins involved in 
transcriptional deregulation of structural and regulatory proteins required for skeletal 
muscle differentiation. This will facilitate us to have a better understanding of the 
myogenic gene regulation at the molecular level which will allow us to develop 
various approaches for effective medical treatment of muscular disorders.  
 
1.9. Perspectives and aims of study 
Based on research studies, the bHLH transcription factor Sharp-1 has been identified 
as an inhibitor of skeletal myogenesis. Sharp-1 is over-expressed in inclusion body 
myositis that exhibits a differentiation defect, and is also associated with loss of 
skeletal muscle mass (Morosetti et al., 2006, Lecomte et al., 2010). While Sharp-1 is 
36 
 
overexpressed in myopathies, the mechanisms by which it regulates myogenesis are 
not completely understood. Besides inhibiting myogenesis, Sharp-1 also blocks 
adipogenic differentiation through the recruitment of a transcriptional co-factor 
methyltransferase G9a to adipogenic promoters (Gulbagci et al., 2009). The role of 
G9a in myogenesis is unknown and the mechanisms underlying Sharp-1-mediated 
repression of myogenesis are unclear. Therefore, this research aims to examine 
whether G9a is involved in myogenic differentiation, and once established, to 
investigate its relationship to Sharp-1 in the regulation of muscle cell differentiation.   
The first part of the study aims to determine if G9a has a role in myogenic 
differentiation.  
• To determine if G9a is involved in myogenic differentiation, both the 
expression level and cellular localisation of G9a are assessed in myoblast 
differentiation. 
• Both gain of function and loss of function studies are used to find out if G9a 
has an effect on myogenic differentiation.  
• In myogenic differentiation, transcription factor MyoD-mediated upregulation 
of p21 which correlates with cell cycle withdrawal is necessary to induce 
terminal skeletal muscle differentiation (Guo et al., 1995, Halevy et al., 1995). 
On the contrary, it was shown that G9a co-operates with CDP/cut and Gfi1 
transcriptional regulators to suppress p21 expression (Nishio and Walsh, 2004, 
Duan et al., 2005). Hence, it is necessary to determine if G9a participates in 
the regulation of a key cell cycle regulator p21 in myogenesis. Cell 




• MyoD is a critical MRF that switches on differentiation genes during 
myogenic differentiation. One of its immediate downstream targets is 
myogenin. Since H3K9me (H3K9 di-methylation), a hallmark of G9a activity, 
associates with transcriptional repression, H3K9me levels on the myogenin 
promoter is assessed in G9a-expressing cells. 
• The G9a SET domain confers its methyltransferase activity. To determine if 
the SET domain is responsible for any G9a-mediated effect in myogenesis, a 
comparison is made between full length G9a and G9a∆SET mutant 
overexpressed in myoblasts. 
• In addition to deletion of the SET domain, a methyltransferase inhibitor, BIX-
01294 is applied in both differentiation assay and ChIP assay to ensure that 
G9a methyltransferase activity is involved in G9a-mediated effect. Phenotypic 
effect, myogenic markers as well as H3K9me levels on the myogenin 
promoter are examined.   
• Many studies showed that G9a is capable of methylating proteins such as      
such as CDYL1, WIZ, C/EBP, Reptin, ACINUS, CENP-A, CENP-B, CENP-
C, TRF1 TRF2 and  p53 and itself (Ueda et al., 2006, Chin et al., 2007, 
Rathert et al., 2008, Huang et al., 2010, Sampath et al., 2007, Pless et al., 
2008, Lee et al., 2010). In addition to these proteins, MyoD also contains a 
similar methylation consensus at Lysine 104. Hence, if G9a has an effect on 
myoblasts differentiation, then determine if its effect is reversible and if G9a 
methylation of MyoD at lysine 104 is required for G9a-mediated effects in 
myogenesis. A rescue assay is performed with re-expression of MyoD and 
MyoD(K104R) in G9a-expressing cells where MyoD(K104R) is refractory to 
G9a methylation.  
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Sharp-1 inhibits myogenic and adipogenic differentiation. However, mechanisms by 
which Sharp-1 represses myogenesis are not well defined. Since G9a is associated 
with Sharp-1 in repression of adipoctyes (Gulbagci et al., 2009), it is interesting to 
find out if G9a is also involved in Sharp-1-mediated inhibition of myogenic 
differentiation. Hence, the second part of the study aims to determine if determine if 
G9a acts as a co-repressor for Sharp-1 in blocking skeletal myogenesis.  
• First, to ensure that data is consistent with previous reports (Azmi et al., 2004), 
the downregulation of Sharp-1 expression is determined in myoblasts. 
• For the same reason as above, Sharp-1-mediated differentiation defects is 
determined using differentiation assay with myoblasts overexpressing Sharp-1. 
• To find out if G9a is involved in Sharp-1-mediated repression, the interaction 
between G9a and Sharp-1 is examined. If they interact, their interacting 
domains will be determined using deletion mutants. In addition, their cellular 
localisations will be investigated to ensure that they exist in the same 
compartment in a cell.   
• G9a di-methylates H3K9. To find out if G9a methylation activity is involved 
in Sharp-1-mediated repression and whether the differentiation defects 
induced by Sharp-1 are similar to G9a, H3K9me levels on myogenin promoter 
are examined in Sharp-1 expressing cells.  
• If G9a can methylate MyoD at lysine 104 as indicated in the first part of the 
study, then to find out if G9a methylation activity is involved in Sharp-1-
mediated repression, methylation levels of MyoD and MyoD(K104R) are 
investigated in Sharp-1 expressing cells. 
• Sharp-1 inhibits MyoD transcriptional activity. To determine if G9a activity 
has any relationship to Sharp-1-mediated repression, MyoD transcriptional 
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activity is examined in cells co-expressed with both Sharp-1 and G9a. In 
addition, to determine if their Sharp-1 and G9a interaction is necessary in 
Sharp-1 repressive effects, MyoD transcriptional activity is also examined in 
cells co-expressed with deleted mutants.  
• It is crucial to investigate if Sharp-1-dependent repression of muscle 
differentiation program relies on G9a activity and expression. Experiments are 
carried out to determine if inhibiting G9a activity or expression in Sharp-1-
expressing cells can remove repressive methylation marks on both H3K9 and 
MyoD and thus restore differentiation. A methyltransferase inhibitor BIX-
01294 and RNAi-mediated reduction of G9a are used in Sharp-1-expressing 
cells.  
• Re-expression of wild type MyoD rescues Sharp-1 defective myogenic 
differentiation (Azmi et al., 2004). To find out if methylation of MyoD at 
lysine 104 is crucial in Sharp-1 inhibitory mechanism, a comparison is made 
in rescue assay with re-expression of MyoD and MyoD(K104R) in Sharp-1-



















Materials and Methods 
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2. Materials and Methods 
2.1. Cell culture and differentiation assays 
HEK293T, NIH3T3, COS7, C3H10T½ cells and Phoenix cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS) and 1x antibiotic-antimycotic. C2C12 cells were cultured at low density 
(50% - 60% confluent) in growth medium (GM) containing DMEM supplemented 
with 20% FBS and 1x antibiotic-antimycotic. For differentiation assays, C2C12 cells 
were cultured at high density (80% - 90% confluent) in GM for a day and then 
switched to differentiation medium (DM, containing DMEM with 2% horse serum 
and 1x antibiotic-antimycotic) for another one to three days. Primary myoblasts 
derived from mice were plated on collagen coated plate and cultured in F-10 medium 
supplemented with 20% FBS and 5 ng/ml basic fibroblastic growth factor (bFGF). 
The following day, the medium was replaced with DMEM supplemented with 2% 
horse serum to induce differentiation. Human myoblast cells (Lonza) were cultured in 
skeletal muscle myoblast basal medium supplemented with 20% FBS (SkGM-2 
BulletKit, Lonza). To induce differentiation, medium was replaced with skeletal 
muscle myoblast basal medium supplemented with 2% horse serum, on the following 
day. All cells were incubated in a 37°C humidified incubator with 5% CO2.  
 
2.2. DNA constructs 
Plasmids FLAG-G9a (1001 aa), FLAG-G9a∆ANK (814 aa), FLAG-G9a∆ANKSET 
(1-476 aa), EGFP-G9a, EGFP-G9a∆SET (1-830 aa), pBabe-G9a, MyoD and 
MyoD(K104R) were kindly provided by Dr. Martin J. Walsh (Mt Sinai School of 
Medicine, New York, USA) and Dr. Vittorio Sartorelli (National Institute of Arthritis, 
Bethesda, USA). GST-Sharp-1 fusion construct was previously created (Azmi et al., 
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2003). Plasmids pBabe-Sharp-1 (cloned into pBabe-puro vector), Myc-Sharp-1 and 
Myc-Sharp-1 bHLH (1-112 aa) (cloned into pCS2 vector) were previously generated 
(Gulbagci et al., 2009). Myc-Sharp-1∆O (368 aa, deletion of orange domain from 130 
aa to 172 aa) and Myc-Sharp-1∆N (1-265 aa) were generated by PCR amplification 
(primers and conditions listed in Table IV) and cloned into Myc-Sharp-1 in pCS2 
vector with BamHI/ApaI sites and Bam HI/EcoRI sites respectively. For luciferase 
reporter assays, a firefly luciferase reporter construct (6E-TATA-Luc) driven by 
herpes simplex thymidine kinase promoter and E-Box elements (CACGTG) (Rossner 
et al., 2008), and a myogenin promoter-driven firefly luciferase reporter plasmid 
(pMyogLuc) (Friday et al., 2000) were used.   
 
2.3. Retrovirus production and infection  
Gene delivery by retroviruses is an efficient tool to overexpress a gene of interest and 
determine its role in a cell model. A retrovirus producer line, Phoenix cell is used for 
the production of retroviruses for transduction into the target cell. For protein 
expression using Phoenix cell, our gene of interest is cloned into the pBabe-puro 
retroviral vector which contains a packaging signal and an antibiotic resistance 
marker for selection. Phoenix cells were plated at a density of 1.5 x 106 cells per 100 
mm-diameter dish. On the 2nd day, cells were transfected with pBabe-puro control 
vector (retroviral vector), pBabe-G9a or pBabe-Sharp-1 (retroviral vector containing 
the genes of interest) using Calcium Phosphate transfection kit (Invitrogen) according 
to the manufacturer’s instructions. On the 3rd day, the medium was replaced with 
C2C12 growth medium (DMEM supplemented with 20% FBS and 1x antibiotic-
antimycotic). The 1st and 2nd (the 4th and 5th day, respectively) viral supernatant 
containing the genes of interest, were collected and filtered through 0.45 µm filters for 
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transduction of target cells. The target cells, C2C12 were plated at a density of 0.3 x 
106 cells per 100 mm-diameter dish. Next day, target cells were transduced with the 
respective viral supernatant in the presence of 4.8 µg/ml of polybrene. After selection 
with 2 µg/ml of puromycin for two days, cells are tested for overexpression of the 
gene of interest and its biological effects. 
 
2.4. Transient transfection and siRNA-mediated knockdown of G9a 
Cells were plated at a density of 6 x 105 cells per 35 mm-diameter plate and 
transfected the next day using Lipofectamine and Plus reagent (Invitrogen) according  
to the manufacturer’s instructions. Co-transfections of pBabe and FLAG-G9a or Myc-
Sharp were carried out in a ratio of 1:9. For siRNA transfection, Sharp-1-expressing 
cells plated at a density of 1 x 105 cells per 35 mm-diameter plate were transfected 
with 100 nM of control scrambled siRNA (non-targeting siRNA control pool, 
Dharmacon) or G9a-directed siRNA (siG9a, on-target SMART pool siRNA targeting 
G9a, Dharmacon) using Lipofectamine RNAiMAX (Invitrogen). Sequences are 
shown in Table III. After 24 hours, cells were either harvested for 
immunoprecipitation assay or selected with 2 µg/ml of puromycin (Sun et al., 2007) 
for two days before plating for differentiation assay.  
 
2.5. The methyltransferase inhibitor BIX-01294  
BIX-01294 (Alexis) has been identified to inhibit G9a methyltransferase activity 
(Kubicek et al., 2007, Gazzar et al., 2008, Chang et al., 2009). In culture, cells in GM 
were incubated with 2.5 µM BIX-01294 for 8 hours and cells in DM were incubated 
with 2.5 µM BIX-01294 for another one to three days before harvesting. As controls, 
cells were treated with the same volume of dimethyl sulfoxide (BIX-01294 is 
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dissolved in 99.9% of dimethyl sulfoxide, according to the manufacturer’s instruction) 
for the same number of days. Following, western blots, IP or ChIP analysis were 
carried out.  
 
2.6. Immunofluorescence (IF) analysis  
Cells were seeded onto coverslips. At the indicated time point of harvest, coverslips 
were rinsed twice with phosphate buffered saline (PBS) and fixed with 4% 
paraformaldehyde for 10 minutes at room temperature. After three washes with PBS, 
the cells were permeabilized with 0.5% Triton-X-100 for 5 minutes. Cells were rinsed 
three times with PBS and incubated with blocking buffer (3% bovine serum albumin) 
for 1 hour. Cells were incubated with primary antibodies: myosin heavy chain (clone 
my32, Sigma, 1:200 dilution) or anti-G9a/EHMT2 (Cell signaling, 1:100 dilution), 
anti-DEC2 (Sigma, 1:50 dilution), anti-FLAG, anti-c-Myc (Sigma, 1:100 dilution) or 
anti-H3K9me2 (Millipore 1:250 dilution) for 1 hour. Cells were rinsed three times 
with PBS and incubated with Alexa Fluor 488 conjugated goat anti-mouse or goat 
anti-rabbit IgG secondary antibody (Molecular Probes, 1:250 dilution) or with Alexa 
Fluor 568 conjugated goat anti-mouse or goat anti-rabbit IgG secondary antibody 
(Molecular Probes, 1:250 dilution) for 1 hour. Cells were rinsed three times with PBS 
and mounted onto a slide with 2 µl DAPI (Vector laboratories). The edges of the 
coverslips were sealed with fingernail polish. The fluorescence images were captured 
using fluorescent microscope (Nikon Eclipse TE 2000-U) with 10x or 20x objective 






2.7. Myogenic index  
Myogenic index was determined by calculating the ratio of nuclei in myosin heavy 
chain-stained myotubes over total nuclei. At least 600 nuclei were counted from three 
different fields. Values were reported as means with standard deviation (shown as 
error bar) and represented as percentage. Statistical significance was determined using 
Student’s t test and p-values were indicated with different degree of significance as * 
(p < 0.05), ** (p < 0.01) or *** (p < 0.001) where p <0.05 were considered to be 
statistically significant.    
 
2.8. Bromodeoxyuridine (BrdU)-based cell proliferation assays 
C2C12 cells were plated on a coverslip at a density of 1 x 104 cells per 35 mm-
diameter plate and cultured in GM or DM to induce differentiation. BrdU assay was 
performed as described in the manufacturer’s instructions (Roche). In brief, cells were 
pulsed with 10 µM of BrdU for 2 hours in GM/DM. Cells were rinsed with PBS and 
then fixed with fixative (70% ethanol, 25% of glycine in water, pH 2) for 20 minutes 
at -20°C. The coverslips were rinsed with PBS for three times and then incubated with 
mouse anti-BrdU solution (1:100 dilution) for 45 minutes at room temperature. 
Following, the coverslips were rinsed with PBS for three times and then incubated 
with anti-mouse Ig-fluorescein (1:125 dilution) for 45 minutes at room temperature. 
Coverslips were rinsed with PBS for three times and mounted onto a slide with 2 µl of 
DAPI (Vector laboratories). The edges of the coverslips were sealed with fingernail 
polish. The fluorescence staining was examined under a fluorescent microscope 
(Nikon Eclipse TE 2000-U) with 10x objective lens and images were captured using 
MetaMorph software version 7.0r3. BrdU-positive-stained cells were determined and 
presented in percentage as means with standard deviation (shown as error bar). At 
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least 600 cells were calculated in three different fields. P values were determined 
using Student’s t test and indicated as *(p < 0.05), ** (p < 0.01) or *** (p < 0.001), 
indicating the level of significance.   
 
2.9. Luciferase reporter assays 
To study gene activity in skeletal muscle, luciferase reporter assays were performed 
using C2C12 myoblasts directly or C3H10T½ fibroblasts. C3H10T½ are fibroblasts 
that can be converted into myoblasts upon transfection with MyoD (Salvatori et al., 
1995). Cells are transfected with 6E-TATA-Luc reporter or pMyogLuc reporter, Myc-
Sharp-1, FLAG-G9a, MyoD and MyoD(K104R). In each transfection, the total 
amount (200 ng) of DNA was kept constant by addition of pCS2-empty vector. After 
48 hours, cells were lysed and assayed for luciferase activity using Dual-luciferase 
reporter assay system (Promega). Luciferase activity was measured using Tecan 
microplate reader and Magellan 6 software. Each transfection was performed in 
triplicates. Values were reported as means with standard deviation (shown as error 
bar). Calculated p values using Student’s t test were indicated as * with different level 
of significance, * (p < 0.05), ** (p < 0.01) or *** (p < 0.001) where p <0.05 was 
considered to be statistically significant.     
 
2.10. Western blot analysis and antibodies 
At the indicated time point of harvest, cells were lysed with RIPA lysis buffer (1% 
Triton X-100, 1 mM EDTA, 50 mM Tris-HCL pH8, 50 mM NaCl, 0.1% sodium 
deoxycholate and 1x Protease inhibitor).  Cells were scraped off from culture plates 
containing lysis buffer and transferred into centrifuge tubes. After 30 minutes, cell 
debris was removed by centrifugation at 13,000 rpm for 10 minutes at 4°C. The 
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protein concentrations were determined using Bradford protein assay reagent (Bio-
Rad laboratories) and spectrophotometer (Shimadzu BioSpec-1601). Proteins were 
denatured in sample buffer by boiling for 5 minutes at 95°C. Proteins were separated 
on (8% - 12%) of SDS-PAGE gels and electrophoretically transferred onto a 
nitrocellulose membrane for western blot assay. The membrane was blocked with 5% 
milk in PBS Tween and then incubated with primary antibodies :  anti-MyoD (M-318, 
Santa Cruz Biotechnology, dilution 1:200), anti-myogenin (M225, Santa Cruz 
Biotechnology, dilution 1:200), anti-troponin T (Sigma, dilution 1:1000), anti-
cyclinD1 (H295, Santa Cruz Biotechnology, dilution1:100), anti-p21 (C-19, Santa 
Cruz Biotechnology, dilution 1:400), anti-FLAG (Sigma, dilution 1:1000), anti-c-Myc 
(Sigma, dilution 1:1000), anti-G9a/EHMT2 (Cell signalling, dilution 1:1000) or anti-
β-actin (Sigma, dilution 1:10000). Following, the membrane was incubated with 
either horseradish-peroxidase-conjugated anti-rabbit or anti-mouse IgG secondary 
antibodies. Western blots were developed using ECL Plus western blotting detection 
reagents (Amersham Biosciences). 
 
2.11. Immunoprecipitation (IP) Assays 
500 µg of cell lysates were incubated with 20 µl anti-c-Myc agarose beads or anti-
FLAG beads (Sigma) rotating overnight at 4oC. Alternatively, 500 µg -1000 µg of cell 
lysates were first incubated with 2 µg of antibody rotating overnight at 4oC and then 
incubated with 20 µl of A/G agarose beads (Santa Cruz) for 2 hours at 4oC with 
rotation. Next, IP beads were washed three times with RIPA lysis buffer rotating at 
4oC for 5 minutes for three times. Lysis buffer was discarded and IP beads were 
boiled in 20 µl of 2x SDS-PAGE loading buffer. The samples were analysed by SDS-
PAGE and western blot.   
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 2.12. GST-pull down assays  
GST-Sharp-1 and GST control proteins were expressed in Escherichia coli BL21 cells 
with Luria-Bertani (LB) medium incubated at 37oC until the OD at 600nm reached 
0.8. These proteins were induced with 0.5 mM IPTG at 37oC for 3 hours. Next, cells 
were centrifuged at 5000 rpm for 10 minutes. Supernatant were discarded and cell 
pellets were resuspended in PBS buffer containing 1x PBS, 1% Triton X-100, 0.1 mM 
Dithiothreitol (DTT) and complete protease inhibitor cocktail (Roche). The solution 
was subjected to sonication in ice bath (10 seconds sonication/ 15 seconds pause/ 5 
cycles). After centrifugation at 10,000 rpm for 10 minutes at 4oC, the soluble fractions 
were incubated with glutathione sepharose 4B beads for 2 hours at 4oC with rotation. 
Beads were centrifuged at 2500 rpm for 2 minutes at 4oC. Supernatant were discarded 
and beads were resuspended in PBS buffer as described above to make a 50% slurry. 
GST proteins were quantified by SDS-PAGE and coomassie blue staining. At the 
same time, in vitro translated protein was prepared using TNT-coupled reticulocyte 
lysate system (Promega) according to the manufacturer's instructions. 10 µg of GST 
proteins or GST-Sharp-1 were incubated with 20 µl of in vitro translated FLAG-G9a 
protein in 200 µl of binding buffer (50 mM Tris-HCL pH8.0, 100 mM NaCl, 0.3 mM 
DTT, 10 mM MgCl2, 10% glycerol, 0.1% NP-40, protease inhibitor) rotating for 2 
hours at 4oC. The beads were washed three times with binding buffer before 
resuspended in SDS-PAGE loading buffer. The samples were analysed by SDS-
PAGE and western blot. Anti-FLAG (Sigma, dilution 1:1000) primary antibody and 
subsequently horseradish-peroxidase-conjugated anti-mouse IgG secondary antibody 




2.13. RNA isolation and reverse transcription polymerase chain reaction (RT-
PCR)  
Total mRNA was isolated using TRIZOL (Invitrogen) according to the 
manufacturer’s instructions. cDNA were made using Avian Myeloblastosis Virus 
(AMV) Reverse transcriptase (Promega) according to the manufacturer’s instructions 
with 4 µg of RNA and 1 µl of oligo (dT) as the primer. cDNA were normalised with 
36B4. Normalised cDNA were used to analyse G9a, MyoD and myogenin mRNA 
levels. Primers sequences are shown in Table I. PCR was carried out using the GoTaq 
Flexi DNA Polymerase (Promega), 1x buffer, 1.5 mM Magnesium Chloride, 0.1 mM 
deoxyribonucleotide triphosphate (dNTPs), 0.5 µg  template, 0.1 µM forward primer, 
0.1 µM reverse primer and water in a total volume of 25 µl. PCR reaction were loaded 
into a PCR thermal cycler under the following conditions : 1 cycle of 95°C for 5 
minutes, followed by indicated number of cycles (as shown in Table II) of 95°C for 1 
minute, 58°C for 45 seconds, 72°C for 1 minute, and ending with 72°C for 10 minutes. 
PCR products were analysed by agarose gel electrophoresis using a (1% - 3%) 
agarose gel in a 1x Tris-acetate-EDTA (0.04M Tris-acetate, 0.001M EDTA) buffer. 
Reverse-transcribed cDNA were also quantified by real-time PCR. 
 
2.14. Chromatin immunoprecipitation (ChIP) assays  
ChIP experiments were performed as described by the manufacturer (Millipore). 
Briefly, cells were fixed in 1% formaldehyde for 10 minutes at 37°C, washed in PBS 
and scraped off from culture plate. Cells were resuspended in SDS Lysis Buffer (50 
mM Tris-Cl pH 8.1, 1% SDS, 10 mM EDTA, 1 mM PMSF, 1 µg/ml aprotinin, 1 
µg/ml pepstatin A). Cells were sheared by sonication to obtain DNA fragments and 
the chromatin were immunoprecipitated with 2 µg antibodies directed against 
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H3K9me2 (histone 3 di-methyl Lysine 9, Upstate), H3K9K14ac (histone 3 acetylated 
lysine 9 and lysine 14, Upstate). The cross-links were heat-reversed (65°C) and DNA 
was purified using phenol-chloroform. DNA level was quantified by Q-PCR using 
primers specific to myogenin promoter sequence and β-actin as described in Table II. 
Each sample was performed in triplicate and the values obtained were normalised to 
β-actin. The results were presented as average with standard deviation (shown as error 
bar). P-values were calculated using Student’s t-test and presented with different level 
of significance as * (p < 0.05), ** (p < 0.01) or *** (p < 0.001). It is important to note 
that ChIP assay measures the amount of a chromatin fraction containing a specific 
antigen relative to the total amount of initial chromatin. Hence, between repeated 
experiments, the ChIP-binding patterns are similar but the enrichment values differs 
due to varying amounts of chromatin applied or different hybridization efficiency.   
 
2.15. Quantitative real-time polymerase chain reaction (Q-PCR)  
The cDNA was amplified using Lightcycler 480 SYBR Green 1 Master Kit (Roche). 
Samples were loaded into Roche Light Cycler 480 (LC480) instrument and light 
cycler 480 software (version 1.3.0.0705) was used for analysis. Primers specific to 




















3.1. G9a inhibits myogenic differentiation  
3.1.1. Expression of G9a decreases upon myogenic differentiation 
Previously, Sharp-1 has been shown to inhibit both myogenesis (Azmi et al., 2004) 
and adipogenesis (Gulbagci et al., 2009). During Sharp-1-mediated repression of 
adipogenesis, methyltransferase G9a was recruited onto C/EBPα and PPARγ2 
promoters to regulate adipocytes differentiation. To investigate if G9a is also involved 
in Sharp-1-mediated inhibition of myogenesis, it was necessary to first examine if 
G9a has any role in the regulation of myogenesis. As a start point, G9a expression 
was examined in proliferating and differentiating C2C12 myoblasts. C2C12 cells 
were cultured and harvested at day 0 (proliferative phase), day 1 and 3 (differentiated 
phase). Total RNA were collected and the mRNA levels of G9a, MyoD, myogenin 
were reverse transcribed and analysed by quantitative reverse transcription 
polymerase chain reaction (QRT-PCR) or semi-quantitative RT-PCR. The values 
obtained were normalised against GAPDH mRNA levels and are presented as relative 
G9a mRNA levels (Figure 3.1.1.A). The cDNA samples were also amplified by 
conventional PCR using primers for G9a, MyoD, myogenin and 36B4 genes (primer 
sequences are shown in table I). The amplified PCR products were then analysed on 
agarose gel electrophoresis (Figure 3.1.1.B). Expression of 36B4 was used as a 
loading control. In both Q-RT-PCR and conventional PCR analysis, G9a mRNA was 
expressed in C2C12 cells in the proliferating myoblasts (72.2%), and its expression 
declined rapidly during differentiation (17.1%, 15.1% and 14.9% for day 1, 2, 3 
respectively). The increased expression of MyoD and myogenin served as a control 
differentiation. In addition, the G9a protein expression was examined by western blot 
in C2C12 cells. β-actin expression was used as an internal control (Figure 3.1.1.C). 
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Similar to mRNA expression pattern, the protein expression of G9a was reduced upon 
induction of differentiation (74.4%, 25.3% and 7.4% for day 0, 1 and 3, respectively), 


















Figure 3.1.1 Expression of G9a in C2C12 myoblasts. 
 The G9a mRNA levels were examined in proliferating (day 0) and differentiating 
(day 1, 3) C2C12 cells. The relative mRNA expression was quantified and 
standardised against the house-keeping gene GAPDH. Values were presented as mean 
with standard deviation (error bar) for three independent experiments (A). The mRNA 
levels of G9a, myogenic markers MyoD and myogenin, and 36B4 (internal control) in 





using semi-quantitative RT-PCR (B). Protein expression levels of G9a, MyoD, 
myogenin, troponin T were also analysed by western blot. β-actin was used as an 
internal control (C).  
 
 
3.1.2. Expression of G9a in primary mouse myoblasts decreases upon myogenic 
differentiation 
In order to further validate the expression of G9a, both semi-quantitative and real-
time RT-PCR were performed using primary mouse myoblasts (Figure 3.1.2.A, B). 
The expression of G9a in differentiating primary mouse myoblasts also showed the 













Figure 3.1.2 Expression of G9a in primary mouse myoblasts. 
G9a mRNA expression levels during primary mouse myoblast differentiation were 
determined. The mRNA levels were normalised to GAPDH and quantified by QRT-




(B). Values for Q-PCR are presented as means with standard deviation (error bar) for 
three independent experiments. 
 
 
3.1.3. G9a remains in the nucleus during myoblast differentiation 
The expression of G9a declines as myoblasts differentiate but the localisation during 
differentiation was unclear. Hence, the localisation of G9a protein in myoblast cells 
undergoing proliferation and differentiation was examined by immunofluorescence 
microscopy. C2C12 cells, cultured in growth medium (GM, proliferation phase) or in 
differentiating medium (DM) for three days to induce differentiation, were fixed for 
immunofluorescence staining. Endogenous G9a was stained with FITC-conjugated 
antibody (green), myosin heavy chain (MHC) was stained with Texas-Red-conjugated 
antibody and nuclei were stained with DAPI. Fluorescence images were captured 
using a 20x objective lens (Figure 3.1.3). G9a was expressed in the nucleus in 
proliferating C2C12 myoblasts and its expression remained nuclear in differentiated 
cells expressing myosin heavy chain. Similar to earlier results, G9a expression was 
lower in differentiated cells compared to proliferating cells. All the results showed 
that G9a declined during differentiation of myoblasts, suggesting that it may be 




















Figure 3.1.3 Localisation of G9a in undifferentiated and differentiating 
myoblasts.  
Localisation of endogenous G9a in day 0 (cells in growth phase) and in day 3 (cells in 
differentiation phase) were observed by immunofluorescence microscopy. 
Differentiated cells were identified by immunofluorescence staining with anti-myosin 
heavy chain antibody (MHC, red). Nuclei were immunostained with DAPI (blue) and 
cellular localisation of G9a (green) was observed. The fluorescence images were 
captured under a microscope using 20x objective lens and MetaMorph software. 
 
 
3.1.4. Overexpression of G9a inhibits myoblast differentiation 
G9a belongs to the methyltransferase family which includes Suv39h1, 
ESET/SETDB1 and Ezh2. Suv39h1 and Ezh2 are down-regulated during myoblast 
differentiation and their overexpression have been reported to inhibit skeletal muscle 
differentiation (Caretti et al., 2004; Mal et al., 2006). As G9a expression also declined 
during myogenic differentiation, I examined if G9a plays a role in myogenesis. A gain 
of function study was done to observe the impact of G9a in differentiation. Phoenix 




vector) or pBabe-G9-expressing retroviruses which were then used to transduce 
C2C12 myoblasts. Overexpression of G9a was determined by western blot analysis 
(Figure 3.1.4.A). C2C12 cells were left untransfected or retrovirally transduced either 
with pBabe or pBabe-G9a. Untransfected or puromycin-selected transduced cells 
were cultured in growth medium (GM) or in differentiating medium (DM) for one day 
or three days. Morphological changes of cells was observed during their proliferation 
phase (undifferentiated cells at day 0) and differentiation phase (day 1 and day 3) 
under a phase contrast microscope using 10x (Figure 3.1.4.B) and 20x objective lens 
(Figure 3.1.4.C). Morphologically, cell alignment was observed on day 1 in 
untransfected (control) and pBabe-expressing cells (control) but not in pBabe-G9a-
expressing cells (Figure 3.1.4.D). Moreover, the number of myotubes was found to be 
distinctly reduced in pBabe-G9a-expressing cells compared with untransfected or 
pBabe-expressing cells. These results suggest that G9a has a role in myogenic 

































Figure 3.1.4 Overexpression of G9a inhibits myogenic differentiation. 
Phoenix cells were transfected with pBabe (vector control) or pBabe-G9a and 
analysed for the expression of G9a. β-actin was used as a loading control (A). C2C12 
cells were left untranfected or transduced with either pBabe- or pBabe-G9a-encoding 
retrovirus. Untransfected or transduced cells were cultured in GM followed by one to 
three days in DM to induce to differentiation. Morphological analysis of myogenic 
differentiation were analysed and captured at 10x magnification (B) or 20x 




showing myoblast proliferation, myoblast alignment, myoblast fusion and myotube 
formation (D).      
   
 
3.1.5. Overexpression of G9a inhibits expression of muscle-specific genes  
To further verify that G9a inhibits myogenic differentiation, the formation of 
multinucleated myotubes was determined by immunostaining with MHC, a marker of 
differentiated myotubes. C2C12 cells-expressing pBabe and pBabe-G9a were cultured 
to proliferate in GM (day 0) or differentiate in DM for one to three days (day 1, 3). At 
the respective time points, undifferentiated and differentiated cells were fixed and 
stained with monoclonal MHC antibody, followed by anti-mouse Texas-red 
conjugated secondary antibody. The nuclei were stained with DAPI. MHC expression 
and myotube formation was severely impaired in C2C12 cells overexpressing G9a in 
day 1 and 3 after differentiation (Figure 3.1.5.A), demonstrating that G9a inhibits 
MHC expression and myogenic differentiation.  
To further substantiate these findings at the molecular level, expression of myogenic 
markers was assessed in pBabe- and pBabe-G9a-expressing cells. pBabe- and pBabe-
G9a-expressing C2C12 cells were cultured in GM or in DM. Undifferentiated cell 
lysate (day 0) and differentiated cell lysates (day 1, 3) were collected and subjected to 
western blot analysis. Protein levels of myogenic differentiation markers myogenin, 
troponin T were examined and β-actin was used as a loading control. The expression 
of myogenin expression was reduced in pBabe-G9a (1.94% and 24.55% at day 1 and 
3 respectively), compared with pBabe controls (7.65% and 27.6% at day 1 and 3 
respectively). Similarly, troponin T levels was obviously reduced in differentiating 
cells expressing G9a (Figure 3.1.5.B). These biochemical changes are consistent with 
morphological and immunofluorescence with MHC staining. Thus, G9a inhibits 
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expression of myogenic differentiation markers and blocks skeletal muscle 
differentiation.  
To examine whether G9a has an impact in primary myoblasts, similar experiments 
were carried out using primary cultures of normal human skeletal myoblasts Human 
primary myoblasts were infected with pBabe- or pBabe-G9a encoding retrovirus. The 
human myoblasts overexpressing pBabe or pBabe-G9a were cultured to proliferate in 
growth medium or differentiate in differentiation medium for three days. Cell lysates 
were collected and subjected to western blot analysis using antibody against G9a, 
troponin T and β-actin (serve as a loading control). Expression of G9a was 
determined (Figure 3.1.4.A) and expression of skeletal muscle differentiation marker 
troponin T was examined (Figure 3.1.5.C). In human myoblasts overexpressing G9a, 
the terminal differentiation marker, troponin T was reduced.  This result further 
validates the earlier tests in transformed C2C12 cells and confirms that G9a 









































Figure 3.1.5 G9a inhibits differentiation and expression of muscle-specific genes.  
pBabe (vector control) and pBabe-G9a infected C2C12 cells were cultured to 
proliferate (day 0) or induced to differentiate (day 1, 3). The extent of differentiation 
was assessed by immunofluorescence staining with myosin heavy chain (MHC, red). 
The nuclei were stained counterstained with DAPI (blue). The images were merged 
and captured at 10x magnification (A). Cell lysates were analysed by western blot for 
myogenic markers myogenin and troponin T. β-actin was used as loading control (B). 
pBabe- (vector control) and pBabe-G9a-expressing human primary myoblasts were 
cultured in GM or induced to differentiate for three days. Cell lysates were analysed 
by western blot for troponin T expression (C). β-actin was used as loading control.    
 
 
3.2. G9a inhibits cell-cycle progression  
3.2.1. Overexpression of G9a promotes myoblast proliferation 
During myoblast differentiation, MyoD upregulates the expression of the cyclin-
dependent kinase (Cdk) inhibitor p21. MyoD-mediated induction of p21 correlates 
with cell cycle withdrawal and cell cycle arrest which is necessary to induce terminal 
skeletal muscle differentiation (Guo et al., 1995, Halevy et al., 1995). However, 
reports have shown that methyltransferase G9a can also suppress the cell cycle 
inhibitor p21 which leads to a delayed cell cycle exit (Nishio and Walsh, 2004, Duan 
et al., 2005). Together, these suggest the likelihood that G9a may also suppress p21 
which will delay cell cycle exit and hence prevent skeletal muscle differentiation. 
Since overexpression of G9a inhibited skeletal muscle differentiation, it was not clear 
if this was due to an impact of G9a in delaying cell cycle exit and thus impairing cell 
differentiation. To elucidate if G9a affects cell proliferation, bromodeoxyuridine 
(BrdU) incorporation assay was performed. Cells that are in S-phase of the cell cycle 
will incorporate BrdU and an analysis of the BrdU-positive signals provides an 
estimate for the fraction of cells in S-phase. C2C12 cells overexpressing pCS2 (vector 
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control) or FLAG-G9a were cultured in GM and pulse-labelled with BrdU. BrdU 
pulse-labelled cells were fixed and immunostained with mouse anti-BrdU antibody, 
followed by anti-mouse Ig-fluorescein. Fluorescence images showed more BrdU-
positive cells in cells overexpressing G9a as compared to control cells (Figure 
3.2.1.A). The percentage of BrdU-positive cells was calculated by counting at least 
600 cells and represented in graph as mean with standard deviation (Figure 3.2.1.B). 
The statistical results showed that significantly, overexpression of G9a induced a 












Figure 3.2.1 Overexpression of G9a promotes myoblast proliferation. 
C2C12 cells were transfected with pCS2 (vector control) or FLAG-G9a and cultured 




anti-BrdU antibody. BrdU-positive cells (green) and DAPI-stained nuclei (blue) were 
examined under a fluorescent microscope with a 20x objective lens (A). The 
percentage of BrdU-positive cells was calculated and presented as means with 
standard deviation (error bar). P-values were calculated using Student’s t-test and 
shown as * (p < 0.05, significant). This experiment was carried out at least twice with 
similar results (B). 
 
 
3.2.2. G9a delays cell cycle exit during differentiation 
During differentiation, myoblasts are required to withdraw from the cell cycle in order 
to express terminal differentiation markers. However, not all the cells terminally 
differentiate but a small population of myoblasts remain undifferentiated. Hence, 
myoblasts are thought to exist both in a quiescent and differentiated state with a low 
proliferative index (Baroffio et al., 1996, Yoshida et al., 1998). To further investigate 
if G9a continues to promote cell cycle progression, similar BrdU incorporation assay 
was performed to assess the proliferative capacity of cells cultured under 
differentiating conditions, unlike the previous cells cultured under proliferating 
condition. Unlike in proliferative state, C2C12 cells overexpressing pCS2 (vector 
control) or FLAG-G9a were cultured to about 80% confluence and then subjected to 
differentiation conditions. The cells were pulse-labelled with BrdU and a green 
fluorescent dye. Fluorescence images revealed that there were more BrdU-positive-
stained cells in G9a-expressing cells than in control cells undergoing differentiation 
(Figure 3.2.2.A). The percentage of BrdU-positive-stained cells was determined, by 
counting the number of BrdU-positive stained cells over a total of at least 600 cells 
(Figure 3.2.2.B). There were significantly more BrdU-positive cells in G9a-
expressing cells (23.8%) compared to control cells (15.4%). Thus, G9a plays a role in 
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promoting cell proliferation and delays cell cycle exit which probably leads to a delay 
















Figure 3.2.2 G9a delays cell cycle exit during myoblast differentiation. 
pCS2- (control vector) or FLAG-G9a-expressing C2C12 cells were induced to 
differentiate for one day and then pulsed-labeled with BrdU. Cells were 
immunostained with anti-BrdU antibody (green) and analysed under a microscope 
with 20x magnification. Nuclei were stained with DAPI (blue) (A). The percentage of 
BrdU-positive cells were determined and presented as means with standard deviation 
(error bar). The p-values were calculated using Student’s t-test and shown as * (p < 







3.2.3. G9a suppresses p21 expression  
Previous studies have shown that G9a is recruited by the transcription regulator 
CDP/cut (CCAAT displacement protein_cut homolog), Gfi (growth factor 
independent 1) and protein UHRF1 (ubiquitin-like, containing PHD and RING finger 
domains 1) to block p21 expression and enhances cell cycle progression (Nishio and 
Walsh, 2004, Duan et al., 2005, Kim et al., 2009). To examine if the alteration in cell 
cycle exit in myoblast is due to G9a-mediated transcriptional repression of p21, 
C2C12 cells overexpressing EGFP (vector control) or EGFP-G9a were cultured in 
both proliferative phase and differentiation phase for one to three days. Cell lysates 
were collected and subjected to western blot analysis for p21 and cyclin D1 (Figure 
3.2.3.). In G9a-expressing cells, the level of p21 expression was clearly reduced as 
cells differentiated. Conversely, the expression of cyclin D1 which is required for G1 
phase cell cycle progression was relatively higher at day 1. The reduction in p21 
expression and the increase in cyclin D1 expression correlate with the BrdU assay 
which demonstrates that G9a enhances myoblast proliferation and delays cell cycle 
exit in C2C12 differentiation.  
 
Figure 3.2.3 G9a suppresses p21 expression and cell-cycle progression.  
C2C12 cells overexpressing EGFP (vector control) or EGFP-G9a were cultured to 




and analysed by western blot for cell-cycle markers cyclin D1 and p21. β-actin was 
loaded as a control.   
 
 
3.3. G9a represses transcription through its methyltransferase activity 
3.3.1. Overexpression of G9a increases H3K9me2 mark on the myogenin 
promoter 
G9a has been shown to preferentially di-methylate histone 3 lysine 9 (Tachibana et al., 
2002, Rice et al., 2003) which correlates with transcriptional repression. To examine if 
there is a link between G9a methyltransferase activity and transcriptional repression of 
muscle-specific genes, chromatin Immunoprecipitation (ChIP) assay was performed to 
assess H3K9me2 changes on the myogenin promoter. EGFP (vector control) and 
EGFP-G9a expressing C2C12 cells were cultured to proliferate (undifferentiated day 
0) and differentiate for two days (differentiated day 2). Cell lysates were subjected to 
sonication to shear the chromatin and then immunoprecipitated with H3K9me2 
antibody. In undifferentiated control cells, myogenin promoter was H3K9me2 which 
declined upon differentiation. This is consistent with data shown in other reports (Mal 
et al., 2002, Caretti et al., 2004). G9a-expressing cells, on the other hand, had 
significantly higher H3K9me2 levels on myogenin promoter in both undifferentiated 
and differentiated cells (Figure 3.3.1.A). Thus, overexpression of G9a leads to an 
increase of H3K9me2 levels at the myogenin promoter which correlates with the 
repression in muscle differentiation gene expression and explains the differentiation 
defects.   
A similar ChIP experiment was repeated with EGFP- and EGFP-G9a-expressing 
C2C12 cells using acetylated H3K9K14ac antibody to assess the level of acetylated 
histones, since a reduction in histone acetylation correlates with reduced gene 
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expression. Acetyl histone H3K9K14 levels were significantly lower in G9a 
expressing cells compared to control cells (Figure 3.3.1.B).  
Therefore, the methyltransferase G9a increases H3K9me2 and reduces H3K9K14ac 
on the myogenic gene promoter which precedes the decrease in the expression of 







Figure 3.3.1 G9a alters histone H3K9me2 and H3K9K14ac levels on myogenin 
promoter. 
EGFP- (vector control) or EGFP-G9a-expressing C2C12 cells were cultured to 
proliferate or induced to differentiate for two days. Cells were analysed by ChIP 
assays to determine the H3K9me2 (A) and H3K9K14ac (B) levels on the myogenin 
promoter. Cell lysates were subjected to immunoprecipitation with H3K9me2 or 
H3K9K14ac antibody and the chromatin were analysed by QPCR using primers for 
the myogenin promoter and beta-actin. The experiments were carried out at least 
twice with values represented as means with standard deviation (error bar). P-values 
were calculated using Student's t-test (* p < 0.05, significant, ** (p < 0.01, highly 
significant).  
 
     
3.3.2. The catalytic SET domain in lysine methyltransferase G9a  
Lysine methyltransferase has a SET domain that is responsible for methylating lysine 





muscle differentiation defect (Caretti et al., 2004, Mal, 2006). The human 
methyltransferase G9a gene contains ankyrin repeats and a catalytic SET domain. The 
ankyrin repeats are approximately 186 amino acids and the SET domain is 
approximately 115 amino acids. G9a SET domain exhibits high sequence similarity to 










Figure 3.3.2 SET domains in methyltransferases.  
The protein sequences of the SET domain in various histone methyltransferases 
(HKMT) with indication of their methylation (met) sites. Identical amino sequences 
of the SET domain are indicated as residues in bold.  
 
 
3.3.3. The SET domain in G9a is required to inhibit differentiation 
A mutagenesis study was necessary to investigate if G9a SET domain is also required 
for the inhibition of skeletal muscle differentiation. The full length G9a encodes a 
protein product of 1001 amino acids whereas the G9a∆SET mutant , has its SET 
domain deleted, encodes a protein product of 830 amino acids (Figure 3.3.3.A). Both 
the wild type and deletion constructs were used in differentiation assay to determine if 
catalytic SET domain is involved in regulating myogenesis.  
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Many studies have established that the SET domain in G9a is responsible for 
H3K9me2 which is associated with gene silencing. In addition, the SET domain in 
other methyltransferases Suv39H1 and Ezh2 were reported to be necessary for the 
inhibition of muscle differentiation (Caretti et al., 2004, Mal, 2006). To examine if the 
SET domain in G9a is necessary for inhibiting myogenic differentiation, a 
differentiation assay was performed with both wild type G9a and G9a∆SET mutant. 
C2C12 cells were cotransfected with EGFP-G9a or EGFP-G9a∆SET mutant and 
pBabe vector at a ratio 9:1. After selection with puromycin for two days, transfected 
cells were cultured for differentiation assay and cell lysates were collected for western 
blot analysis. The protein expression of both EGFP-G9a and EGFP-G9a∆SET were 
detected in C2C12 cells (Figure 3.3.3.B). In addition, the undifferentiated cells (day 0) 
and differentiated cells (day 3) were immunostained with MHC antibody, followed by 
Texas-red conjugated antibody while the nuclei were stained with DAPI. Under the 
differentiation conditions, G9a-expressing cells exhibited a reduction in expression of 
MHC-positive cells and differentiated myotubes compared to control cells. However, 
G9a∆SET-expressing cells did not show differentiation defect (Figure 3.3.3.C), 
indicating that the SET domain in G9a appears necessary for inhibition of myotube 
formation and cell differentiation. To quantify the differentiation defects, myogenic 
index was determined. Myogenic index is defined as the ratio of the number of nuclei 
within the MHC-positive myotubes over a total of at least 600 nuclei. The myogenic 
index in EGFP-, EGFP-G9a- and EGFP-G9a∆SET-expressing cells was calculated 
and presented as mean with standard deviation. This statistical study showed that 
there was a significant (p < 0.01) reduction in the level of MHC expressed in G9a-





















Figure 3.3.3 The SET domain in G9a is required to inhibit differentiation. 
A diagram that represents full length G9a (1-1001 aa) and its deletion construct 
G9a∆SET (1-830 aa). Full length G9a contains 6 contiguous ankyrin repeats and a 
SET domain. G9a∆SET has its SET domain deleted (A). The G9a expression in 
EGFP- (vector control), EGFP-G9a- and EGFP-G9a∆SET-expressing cells were 
analysed by western blot. β-actin was used as a loading control (B). Myotube 
formation was assessed in undifferentiated cells (day 0) and differentiated cells (day 3) 
by immunofluorescence staining using anti-MHC antibody (red). Nuclei were stained 
with DAPI (blue). Images were captured under a microscope using 20x magnification 
(C). The extent of myogenic differentiation was quantified by myogenic index. 




positive stained nuclei to the total nuclei in each field (at least 600 nuclei calculated in 
each field). Values were presented as means with standard deviation (error bar) and p-
values were calculated using Student's t-test (**, p < 0.01, highly significant). Results 
are representative of at least two separate experiments (D). 
 
 
3.3.4. The SET domain in G9a is required to inhibit expression of muscle-specific 
genes 
In the same set of experiments, cell lysates, collected at undifferentiated day (day 0) 
and differentiated day (day 1, 3), were subjected to western blot analysis to determine 
the expression of myogenic differentiation markers, myogenin and troponin T. β-actin 
was used as an internal control. While both myogenin and troponin T expression was 
reduced in EGFP-G9a expressing cells, the expression levels in EGFP-G9a∆SET-
expressing cells were about the same as that in control cells (Figure 3.3.4). Together, 
these results demonstrated during G9a-mediated inhibition of muscle differentiation, 
its methyltransferase activity conferred by its SET domain was necessary for the 







Figure 3.3.4 The SET domain in G9a is required to inhibit expression of muscle-
specific genes.  
C2C12 cells overexpressing EGFP- (vector control), EGFP-G9a- and EGFP-
G9a∆SET-expressing cells were cultured to proliferate (day 0) or induced to 




myogenic differentiation markers such as myogenin and troponin T. β-actin 
expression was used as a loading control. 
 
 
3.4. G9a methyltransferase inhibitor BIX-01294 induces early onset of 
differentiation  
3.4.1. Titration of BIX-01294 in muscle cells 
Previous results showed that G9a was dependent on its methyltransferase activity to 
block muscle differentiation. G9a methyltransferase activity has been shown to be 
inhibited by BIX-01294 (a diazepin-quinazolin-amine derivative) (Chang et al., 2009, 
Kubicek et al., 2007). To further determine that G9a-mediated differentiation defect 
was dependent on its methyltransferase activity, BIX-01294 was used in G9a-
overexpressing cells. A range of 0 µM to 6 µM BIX-01294 has been used to block 
methyltransferase activity in various cell lines (Kubicek et al., 2007, Gazzar et al., 
2008, Chang et al., 2009). To determine the optimal BIX-01294 concentration in 
C2C12 cells that was non-toxic, C2C12 cells cultured in both GM and DM for two 
days were treated with BIX-01294 ranging from 0 µM to 6 µM, from the beginning in 
GM. Differentiated cells were stained with MHC antibody. Immunofluorescence 
analysis showed that C2C12 cells exhibited earlier and enhanced myotube formation 
with 2.5 µM of BIX-01294 (Figure 3.4.1). At concentration higher than 4 µM BIX-
01294 led to cell death. Therefore for subsequent experiments, cells were treated with 



































Figure 3.4.1 Titration of BIX-01294 in muscle cells.  
C2C12 cells were treated with different concentrations of BIX-01294 and induced to 
differentiate for two days. Myogenic differentiation was analysed by 
immunofluorescence staining MHC antibody (red) and nuclei were stained with DAPI 




3.4.2. BIX-01294 induces early onset of differentiation  
The extent of differentiation in BIX-01294 treated cells was closely re-examined with 
more assays performed. C2C12 cells were cultured to induce differentiation for three 
days and treated with DMSO (control) or 2.5 µM BIX-01294. Differentiated cells 
were immunostained with MHC antibody and assessed. In comparison with the 
control-treated cells, BIX-01294-treated cells clearly exhibited more MHC-expressing 
cells (Figure 3.4.2.A). Therefore, the G9a-inhibitor blocks endogenous G9a 
methyltransferase activity and induces earlier MHC expression and myotube 
formation. To assess the extent of the myogenic differentiation induced by BIX-01294, 
myogenic index was determined. At least 600 nuclei from the immunofluorescence 
images were counted (Figure 3.4.2.B). BIX-01294 induced a significant increase in 
myogenic differentiation, with 30% more of MHC-positive cells compared to 




















Figure 3.4.2 BIX-01294 induces early onset of differentiation. 
C2C12 cells were induced to differentiate for three days and treated with DMSO 
(control) or 2.5 µM BIX-01294 to block endogenous G9a methyltransferase activity. 
Myotube formation in the differentiated cells were compared and analysed by 
immunofluorescence staining. Nuclei were stained with DAPI (blue) and myotube 
was stained with myosin heavy chain (MHC, red). The images were viewed under a 
microscope at a 20x magnification (A). The extent of myogenic differentiation was 
examined by myogenic index. At least 600 nuclei were scored in each field and the 
values were presented as means with standard deviation (error bar). P-values were 
determined and shown as * (p < 0.05, significant). Results are representative of at 
least two independent experiments (B).  
 
 
3.4.3. BIX-01294 induces early expression of muscle-specific genes during 
differentiation 
In addition, cell lysates were collected and analysed by western blot for differentiation 




cells, a higher level of both myogenin and troponin T expression was observed 
(Figure 3.4.3.A). Similarly, BIX-treated-differentiated cells express higher myogenin 
mRNA levels than control cells (Figure 3.4.3.B). These data demonstrate that BIX-
01294 blocks endogenous G9a methyltransferase activity on myogenic differentiation 
and induces higher expression of muscle differentiation genes and myotubes 









Figure 3.4.3 BIX-01294 induces early expression of muscle-specific genes.  
C2C12 cells cultured in GM (day 0) or DM (day 1, 3) were either treated with DMSO 
(control) or 2.5 µM BIX-01294 to block endogenous G9a methyltransferase activity. 
Cell lysates at day 0, 1, 3 of cell differentiation were collected and analysed by 
western blot for differentiation marker myogenin and troponin T. β-actin was used as 
a loading control (A). Total RNA was extracted from these cells and analysed for 
myogenin mRNA levels by Q-PCR. These experiments were performed at least twice. 
Values obtained were standardised against GAPDH (B).    
 
 
3.4.4. BIX-01294 induces expression of muscle-specific genes in proliferating 
myoblasts 
Myoblasts proliferate in the presence of growth factors and differentiate only upon the 




myoblasts, G9a is highly expressed (Figure 3.1.1 - 3.1.2) and overexpression of G9a 
promotes cell cycle progression (Figure 3.2.1 - 3.2.3) and inhibits muscle 
differentiation (Figure 3.1.3 - 3.1.4). On the other hand, BIX-01294 induces early 
onset of differentiation genes (Figure 3.4.2- 3.4.3). To examine if inhibition of G9a 
can lead to expression of differentiation genes in proliferation conditions, C2C12 cells 
in proliferating culture were treated with DMSO (control) or 2.5 µM of BIX-01294. 
Cell lysates were collected and analysed by western blot for early myogenic 
differentiation marker, myogenin. BIX-01294-treated cells expressed higher levels of 
myogenin even in the presence of growth factors (Figure 3.4.4.A). Thus, inhibiting 
endogenous G9a activity in proliferating myoblasts can also induce expression of 
muscle differentiation marker which is usually not expressed in undifferentiated 
myoblasts. Consistently, myogenin mRNA levels were significantly increased (p< 




Figure 3.4.4 Inhibition of G9a induces expression of muscle-specific genes in 
proliferating myoblasts.   
C2C12 cells were treated with DMSO or 2.5 µM BIX-01294 in growth medium. 
Myogenin protein levels were analysed by western blot and standardised to β-actin 
levels (A). Myogenin mRNA levels were analysed by Q- PCR and standardised to 
GAPDH. The experiment was done at least twice (B). 
 
 
3.4.5. BIX-01294 reduces H3K9me2 on myogenin promoter 
To examine the impact of BIX-01294 on H3K9me2 on myogenin promoter, C2C12 
cells were cultured with DMSO (control) or 2.5 µM of BIX-01294 in GM and then in 
DM to induce differentiation for two days. Undifferentiated cells (day 0) and 
differentiated cells (day 2) were harvested and subjected to ChIP assay. In both types 
of treatment, H3K9me2 levels on the promoter declined as cells differentiated.  
Compared to undifferentiated day 0 cells, BIX-01294-treated cells showed a 
significantly lower (4-fold) H3K9me2 on myogenin promoter. Similarly, upon 




H3K9me2 levels on the myogenin promoter (Figure 3.4.5). Thus, BIX-01294 reduces 
G9a-dependent H3K9 me2 on myogenin promoter in both proliferating and 
differentiating cells, leading to earlier transcriptional upregulation of myogenic 







Figure 3.4.5 BIX-01294 decreases H3K9me2 on myogenin promoter.  
C2C12 cells were treated with 2.5 µM of BIX-01294 and induced to differentiate for 
0, 2 days. ChIP analysis of H3K9me2 on myogenin promoter was assessed. 
Chromatin was immunoprecipitated with H3K9me2 antibody and analysed by Q-PCR 
using primers for the myogenin promoter. Primers for β-actin gene were used as an 
internal control. Values were reported as means with standard deviation (error bar). 
Results are representative for at least two independent experiments. P-values were 




3.5. siRNA knockdown of G9a induces early onset of differentiation 
3.5.1. siRNA-mediated knockdown of G9a in human primary myoblasts induces 
early expression of terminal differentiation genes  
It has been shown that siRNA-mediated knockdown of G9a promoted early onset of 
C2C12 myoblast differentiation (Ling et al., 2012). Since C2C12 are immortalized 
mouse cell line, it was necessary to ensure that the same effect can be achieved in 




with scrambled siRNA control or siRNA targeted to G9a (siG9a). Myoblasts were 
cultured to proliferate in growth medium or induced to differentiate for three days in 
differentiating medium. The efficiency of G9a knockdown was determined (Figure 
3.5.1.A) and the expression of the myogenic differentiation gene, myogenin and 
troponin T were also examined by western blotting (Figure 3.5.1.B). siRNA 
knockdown of G9a in human myoblasts also induced higher expression of both 
myogenin and troponin T genes that was very similar to the pattern seen using C2C12 








Figure 3.5.1 siRNA-mediated knockdown of G9a in human primary myoblasts 
induces early expression of differentiation genes. 
 Human myoblast cells were transfected with scrambled control siRNA or G9a siRNA 
(siG9a) and induced to proliferate (day 0) or differentiate (day 3). Cell lysates were 
analysed by western blot for G9a expression (A). Cell lysates were collected for 
western blot analysis using myogenin and troponin T antibodies (B). β-actin was used 








3.6. BIX-01294 reverses G9a-mediated inhibition of myogenesis 
3.6.1. Inhibition of G9a activity with BIX-01294 rescues differentiation block 
To investigate if BIX-01294 can reverse G9a-mediated inhibition of myogenic 
differentiation, C2C12 cells overexpressing EGFP-G9a were treated with 2.5 µM 
BIX-01294 or DMSO (control) and induced to differentiate for two days. 
Differentiated cells were stained with MHC antibody and fluorescence images were 
analysed. An increase in MHC-positive cells and myotubes were apparent in G9a 
overexpressing cells treated with 2.5 µM of BIX-01294 than controls (Figure 3.6.1.A).  
The extent of myogenic differentiation in G9a-expressing cells with control or BIX-
01294 treatment was further quantified by myogenic index. The result showed a very 
significant recovery of myogenic differentiation with BIX-01294 (Figure 3.6.1.B). At 
the same time, the expression of the muscle differentiation genes was examined in 
these cells. Cell lysates were collected and subjected to western blot analysis for 
troponin T. Compared to control G9a-expressing cells, BIX-01294-treated G9a-
expressing cells showed improved troponin T expression (Figure 3.6.1.C). Thus, BIX-




























Figure 3.6.1 BIX-01294 blocks G9a-mediated inhibition of myotube formation 
and muscle-specific genes.    
C2C12 cells overexpressing EGFP-G9a were treated with DMSO (control) or 2.5 µM 
of BIX-01294 and induced to differentiate for two days. Myogenic differentiation was 
analysed by immunofluorescence staining using myosin heavy chain (MHC, red) 
antibody. Nuclei were stained with DAPI (blue). The images were examined under a 
fluorescence microscope at a 10x magnification (A). The extent of myogenic 
differentiation was assessed in EGFP-G9a-expressing cells, treated with DMSO 
(control) or 2.5 µM BIX-01294. Myogenic index, determined from at least 600 nuclei, 
was presented as means with standard deviation (error bar). These experiments were 
conducted at least twice. P-values were calculated and indicated as *** (p < 0.001, 
highly significant). (B). Cell lysates from day 0, 1, 3 of differentiated cells were 





3.7. Re-expression of MyoD rescues G9a-mediated inhibition of myogenesis 
3.7.1. MyoD(K014R) is more effective in rescuing the differentiation defect 
imposed by G9a compared to wild type MyoD 
Apart from H3K9, G9a has also been recognized for its ability to methylate non-
histone proteins such as CDYL1, WIZ, ACINUS and C/EBPβ (Rathert et al., 2008). 
Both the human and mouse MyoD cDNA sequence also displayed a similar G9a-
methylation consensus motif RK at K104. To test if G9a-mediated repression of 
differentiation is reversible and whether re-expression of MyoD can rescue G9a-
mediated differentiation defect, differentiation assays were performed. Since MyoD 
activity can be inhibited by G9a methylation, a mutant MyoD(K104R) (with point 
mutation of 104 lysine to arginine) was also tested. C2C12 cells were transduced with 
pBabe-G9a and selected with puromycin for two days. Puromycin-selected cells 
expressing G9a were then transfected with pCS2 (vector control), MyoD and 
MyoD(K104R) mutant. A day post-transfection, cells were induced to differentiate for 
three days. Cell lysates were collected and analysed by western blot. Transfected G9a, 
wild type and MyoD(K104R) were expressed in cells (Figure 3.7.1.A). Differentiation 
was monitored by MHC staining. Re-expression of MyoD partially restored 
differentiation in G9a overexpressing cells and the rescue was better with equivalent 
amounts of MyoD(K104R) mutant (Figure 3.7.1.B). This indicated that MyoD can 
rescue differentiation defects but since MyoD may still be methylated and kept 
inactive by G9a, MyoD(K104R) mutant can rescue differentiation to a greater extent.  
The extent of the myogenic differentiation was assessed. Both MyoD and 
MyoD(K104R) were able to rescue the differentiation block imposed by G9a, with 
MyoD(K104R) showing a significantly stronger rescue (Figure 3.7.1.C). Similar 
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rescue experiment was performed using CH310T1/2 cells with identical results 


















Figure 3.7.1 MyoD(K104R) is more effective in rescuing the differentiation defect 
imposed by G9a compared to wild type MyoD.  
FLAG-G9a-expressing C2C12 cells were transfected with pCS2 (control), MyoD and 
MyoD(K104R) and induced to differentiate for three days. G9a expression in cells 
was determined by western blot (A, upper panel). MyoD expression in cells 
overexpressing FLAG-G9a with pCS2(control), MyoD or MyoD(K104R) was 
determined by western blot. β-actin act as a loading control (A, lower panel). 




myosin heavy chain (MHC, red) antibody. Nuclei were stained with DAPI (blue). 
Images were captured under a microscope with 10x magnification (B). Myogenic 
index was determined from at least 600 nuclei and presented as means with standard 
deviation (error bar). P-values were calculated using Student’s t-test and shown as 
*** (p<0.001, highly significant). The experiments were performed at least twice with 
comparable results (C).  
 
 
3.7.2. Re-expression of MyoD(K104R) in G9a overexpressing cells rescues MyoD 
target gene expression to a higher level than MyoD 
To examine skeletal muscle protein expression, both undifferentiated (day 0) and 
differentiated (day 2) cell lysates were collected and analysed by western blot for 
troponin T expression. Troponin T was expressed to a higher level in cells re-
expressing MyoD(K104R) compared to MyoD (Figure 3.7.2). Together, these data 
suggested that the G9a is capable of methylating and inhibiting MyoD from activating 
muscle gene expression. Increasing MyoD levels reverses the inhibitory effect of G9a 







Figure 3.7.2 Re-expression of MyoD(K104R) in G9a overexpressing cells rescues 
MyoD target gene expression to a higher level than MyoD.  
FLAG-G9a-expressing C2C12 cells were transfected with pCS2 (control), MyoD and 




differentiation gene troponin T expression was assessed in cells by western blot. β-
actin was used as a loading control.  
 
 
3.8. Sharp-1 inhibits myogenic differentiation  
Together, earlier results indicate that G9a has an inhibitory role in myogenic 
differentiation. As G9a is a transcriptional co-repressor that needs to associate with 
transcription factors to inhibit muscle gene transcription, it is necessary to identify the 
transcription factor which recruits G9a to the myogenin promoter. On the other hand, 
Sharp-1 has been identified as a transcription repressor in both myogenesis and 
adipogenesis. While inhibiting adipogenic differentiation, Sharp-1 recruits G9a to the 
adipogenic promoter. However, Sharp-1 mechanism in inhibiting myogenic 
differentiation is not well-defined and it not known if Sharp-1 also recruits G9a to 
regulate myogenesis. Therefore, there is a need to determine the association between 
Sharp-1 and G9a and if G9a is involved in Sharp-1-mediated repression.  
 
 
3.8.1. Sharp-1 expression declines upon myogenic differentiation 
It is important to ensure uniformity and consistency with published data and hence the 
pilot experiment is to confirm that the decline in Sharp-1 expression levels during 
myoblast differentiation is observed. Cells were cultured to proliferate and then 
induced to differentiate for one to three days. Cell lysates were collected at the 
respective time points and Sharp-1 mRNA levels were reversed transcribed and 
analysed by Q-RT-PCR using primers for mSharp-1 and GAPDH (primer sequences 
are shown in table II). The relative Sharp-1 mRNA expression values obtained were 
normalised against GAPDH mRNA levels which serve as an internal control. Sharp-1 
mRNA expression declined during muscle cells differentiation (Figure 3.8.1.). This 
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result is similar to our previous study which showed that Sharp-1 downregulated 








Figure 3.8.1 Expression of Sharp-1 in C2C12 myoblasts.                     
Sharp-1 mRNA levels were analysed in C2C12 cells cultured in GM (day 0) or 
induced to differentiate for one to three days (day 1, 3). Total RNA was isolated and 
Sharp-1 mRNA levels were analysed by RT-PCR and Q-PCR as described in 
materials and methods. Quantified relative amount of Sharp-1 mRNA were 
normalised to house-keeping gene GAPDH and presented in graph as mean with 
standard deviation (error bar). Results are representative of at least two separate 
experiments.   
 
 
3.8.2. Overexpression of Sharp-1 inhibits differentiation 
The expression of Sharp-1 declines as myoblasts differentiate and studies have shown 
that overexpression of Sharp-1 inhibits myogenic differentiation (Azmi et al., 2004). 
Similar differentiation assay was conducted to confirm consistency with previous 
report. C2C12 cells were co-transfected with pCS2 (vector control) or Sharp-1 and 
pBabe-puro at a ratio of 9:1. After selection with puromycin, cells were used for 
induced to differentiate for three days. The expression of Sharp-1 and loading control 




Sharp-1-expressing C2C12 cells were immunostained MHC antibody. More MHC-
expressing myotubes were observed in control cells than in Sharp-1-expressing cells 
(Figure 3.8.2.B). The extent of the myotube formation was quantified using myogenic 
index with at least 600 nuclei counted. Compared to control cells, there was a 
significance (p < 0.01) reduction in level of MHC expressed in Sharp-1-expressing 
cells (Figure 3.8.2.C). Hence, the result is in line with previously reported data (Azmi 





























Figure 3.8.2 Overexpression of Sharp-1 inhibits myoblast differentiation. 
C2C12 cells were transfected with pCS2 (control) or Myc-Sharp-1 and pBabe-puro at 
a ratio of 9:1. After selection with puromycin for two days, transfection-positive cells 
were cultured to proliferate in growth medium (day 0) or induced to differentiate in 




was determined using western blot analysis and β-actin was used as a loading control 
(A). Day 3 differentiated cells were immunostained for terminal differentiation 
marker myosin heavy chain (MHC) primary antibody and Texas-red secondary 
antibody. Nuclei were counterstained with DAPI (blue) (B). The extent of myotube 
formation was determined using myogenic index. The values were reported in the 
graph are means with standard deviation (error bars) from at least three separate 
experiments. The significance level are presented, p<0.01 (C).  
 
 
3.8.3. Overexpression of Sharp-1 inhibits expression of MyoD target genes 
The expression of myogenin and troponin T were examined in the total cell lysates 
collected from proliferating cells (day 0) and differentiating cells (day 1, 3). In 
addition to immunofluorescence analysis of MHC, biochemical analysis of terminal 
differentiation markers showed that myogenin and troponin T were reduced in C2C12 
cells overexpressing Sharp-1 (Figure 3.8.3). These morphological and biochemical 
results are similar to those reported previously in literature. Thus, Sharp-1 inhibits 









Figure 3.8.3 Sharp-1 inhibits expression of MyoD target genes. 
Cell lysates were collected from day 0, 1 and 3 of control- and Sharp1-expressing 




3.9. Sharp-1 associates with G9a  
3.9.1. G9a deletion mutant constructs 
Since Sharp-1 inhibits myogenic differentiation (Azmi et al., 2004) and G9a on its 
own also inhibits myogenesis, I next tested the possibility that Sharp-1 associates with 
G9a to inhibit muscle gene expression and myogenic differentiation. G9a contains an 
ankyrin repeats and a catalytic SET domain. To define the domain in G9a required for 
association with Sharp-1, full length G9a was used along with deletion mutant lacking 
the ankyrin repeats (G9a∆ANK) or both ankyrin repeats and the SET domain 









Figure 3.9.1 A schematic representation of G9a and its deletion mutants.  
A diagram that represents full length G9a (1-1001 aa) and truncated constructs 
G9a∆ANK (814 aa) and G9a∆ANKSET (1-476 aa). Full length G9a contains 6 
contiguous ankyrin repeats and a SET domain. G9a∆ANK has its ankyrin repeats 










3.9.2. Sharp-1 associates with G9a through its ankyrin repeats  
While C2C12 mouse myoblast is the most appropriate cell line to use for interaction 
study, it is also a difficult-to-transfect cell line. Nonetheless, the important interaction 
study using endogenous G9a and Sharp-1 in myoblasts was also performed and shown 
in Figure 3.9.7. Here, instead of C2C12, a common highly-transfectable adherent cell 
lines such as 293T cells were cotransfected with Myc-Sharp-1 and full length FLAG-
G9a or FLAG-G9a∆ANKSET mutant. The expression of FLAG-G9a, FLAG-
G9a∆ANKSET and Myc-Sharp-1 was determined by western blot analysis. Cell 
lysates were immunoprecipitated with anti-c-Myc-agarose beads and 
immunoprecipitates were analysed by western blot with anti-FLAG antibody. FLAG-
G9a, FLAG-G9a∆ANKSET and Myc-Sharp-1 were expressed in cells. Immunoblot 
analysis showed that only full length FLAG-G9a interacted with Sharp-1 (Figure 
3.9.2.A). This indicated that the ANK and/or SET domain of G9a is necessary for 
association with Sharp-1. Similar immunoprecipitation assays were performed with 
FLAG-G9a, FLAG-G9a∆ANK and Myc-Sharp-1. Deletion of the ankyrin domain in 
G9a abrogated its interaction with Sharp-1 (Figure 3.9.2.B). These demonstrated that 

























Figure 3.9.2 Sharp-1 associates with G9a through its ankyrin repeats. 
A diagram that represents full length G9a (1-1001 aa) contains 6 contiguous ankyrin 
repeats and a SET domain. G9a∆ ANK (814 aa) with ankyrin repeats domain deleted 
and G9a∆ANKSET (1 -476 aa) with both ankyrin repeats domain and SET domain 
deleted) (A). 293T cells were co-transfected with Myc-Sharp-1, FLAG-G9a or, 
FLAG-G9a∆ANKSET (A) or FLAG-G9a with FLAG-G9a∆ANK (B). Cell lysates 
and immunoprecipitates were anaylzed by western blot with anti-FLAG and anti-c-
Myc antibodies. β-actin was used as an internal loading control.  
 
 
3.9.3. Sharp-1 deletion mutant constructs 
Sharp-1 contains a basic region, a helix-loop-helix (HLH) domain, an orange (O) 
domain and Glycine/Alanine rich C-terminus. Several deletion constructs were 




contains only the N-terminus with basic and HLH domain; Sharp-1∆O mutant and 
Sharp-1∆C mutant have their orange domain or C-terminus truncated respectively. 
Sharp-1∆O mutant and Sharp-1∆C mutant were generated by PCR using primers and 
annealing temperatures as shown in table IV and recloned into BamHI/AscI sites and 









Figure 3.9.3 A schematic diagram of Sharp-1 and its deletion mutants. 
A diagram that represents full length Sharp-1 (1-411 aa) and its truncated construct 
Sharp-1 bHLH (1-112 aa), Sharp-1 ∆O (368 aa), and Sharp-1 ∆N (1-265 aa). Sharp-1 
contains a DNA binding basic domain, helix-loop-helix (HLH) domain, an orange 
domain and a Glycine/Alanine rich region. Sharp-1 bHLH consists of only the N-
terminus with basic domain and HLH domain. Sharp-1 ∆O has its orange domain 
deleted and Sharp-1 ∆C has its C-terminus deleted as indicated.  
 
 
3.9.4. G9a associates with Sharp-1 through its C-terminus spanning amino acid 
173 to 265 
Immunofluoresence studies were carried out to determine the subcellular localisation 
of each protein. C2C12 cells were co-transfected with FLAG-G9a and Myc-Sharp-1 




its mutants demonstrated punctuate staining and remained localised in the nucleus 
(Figure 3.9.4.A). To identify the region in Sharp-1 that binds to G9a, 
immunoprecipitation assay was performed using G9a, full length Sharp-1 and its 
mutants. Similar to figure 3.9.2, instead of C2C12, highly transfectable 293T cells 
were co-transfected with FLAG-G9a and Myc-Sharp-1 or its mutants. Cell lysates 
were subjected to immunoprecipitation with anti-c-Myc agarose beads and western 
blot analysis. Immunoprecipitates demonstrated that all Sharp-1 constructs except 
Myc-Sharp-1-bHLH interacted with G9a (Figure 3.9.4.B) and the region spanning 






































Figure 3.9.4 Localisation of Sharp-1 mutants. 
Immunofluorescence staining showing nuclear staining of Myc-Sharp-1, its mutants 
(red) and FLAG-G9a (green) in C2C12 cells. Nuclei were stained with DAPI (blue) 
(A). 293T cells were co-transfected with FLAG-G9a and Myc-Sharp-1 or its mutants 
as shown. Whole cell lysates were immunoprecipitated with anti-c-Myc agarose beads. 
Cell lysates and immunoprecipitates were analysed by western blot with anti-FLAG, 





3.9.5. G9a co-localises with Sharp-1 in the nucleus 
Sharp-1 associates with G9a and to ensure that they co-exist in the nucleus, co-
localisation of G9a and Sharp-1 was examined. Mammalian cells such as COS 7 cells, 
NIH3T3 cells, C3H10T½ cells and C2C12 cells were co-transfected with FLAG-G9a 
and Myc-Sharp-1. The cells were immunostained with G9a and Myc antibodies and 
the nuclei were stained with DAPI. The fluorescence images were merged to 
determine co-localisation as indicated by the yellow fluorescence. Both G9a and 
Sharp-1 are localised in the nucleus in all types of cells indicating that their 













Figure 3.9.5 G9a co-localises with Sharp-1 in the nucleus. 
NIH3T3, COS7, C3H10T½ and C2C12 cells were co-transfected with Myc-Sharp-1 
and FLAG-G9a. Co-localisation of Sharp-1 and G9a was analysed by 
immunofluorescence staining using anti-c-Myc antibody (green) and anti-G9a 




co-localisation of these proteins was visualized by yellow fluorescence. Images were 
captured under a microscope with 20x magnification. 
 
 
3.9.6. G9a interacts directly with Sharp-1 
G9a associates with Sharp-1 and to further determine whether interaction between the 
two proteins is direct, a glutathione S-transferase (GST) pull down assay was 
performed. GST and GST-Sharp-1 were induced with isopropyl-beta-D-
thiogalactopyranoside in E.coli BL21(DE3) cultures. GST proteins were purified 
using Glutathione Sepharose 4B beads and detected by coomassie blue staining on 
SDS-PAGE gel. The amount of GST protein (indicated as **) and GST-Sharp-1 
protein (indicated as *) were quantified (Figure 3.9.6.A). FLAG-G9a was transcribed 
and translated in vitro using TNT coupled reticulocyte lysate system (Promega). The 
same amount (10 µg) of GST and GST-Sharp-1 proteins were incubated with FLAG-
G9a, followed by glutathione-sepharose beads. Proteins immobilized on glutathione-
sepharose beads were subjected to western blot analysis with anti-FLAG antibody. 10% 
of in vitro translated G9a protein was loaded as a control. GST-Sharp-1, but not GST, 
interacted with FLAG-G9a (Figure 3.9.6.B), demonstrating that G9a interacts directly 










Figure 3.9.6 G9a interacts directly with Sharp-1. 
Recombinant GST (**) and GST-Sharp-1 (*) fusion proteins expressed in E.coli were 
detected by coomassie blue staining (A). In vitro translated FLAG-G9a was incubated 
with GST or GST-Sharp-1 fusion proteins to determine its direct protein interaction. 
10% of FLAG-G9a used in pull-down assay was used as input and detected by 
western blot with anti-G9a antibody (B). 
 
 
3.9.7. G9a interacts with Sharp-1 in myoblasts  
The association of G9a and Sharp-1 was clear. Earlier studies showed that the proteins 
were expressed in the nucleus in both proliferating myoblasts and differentiated 
myotubes. In addition, an immunoprecipitation study using 293T cells showed that 
they interact. However, 293T cells are non-muscle cells. Hence, the following 
immunoprecipitation assay was required to ensure that if they also interact in 
myoblasts undergoing proliferation and differentiation. As there was some technical 
difficulty with antibody in detecting endogenous Sharp-1, C2C12 cells were 
transfected with Myc-Sharp-1. Cells were induced to proliferate in GM or induced to 
differentiate for two days in DM.  Both undifferentiated and differentiated cell lysates 
were collected and analysed by western blot for the expression of endogenous G9a 
and overexpression of Myc-Sharp-1. Cell lysates were subjected to 
immunoprecipitation with anti-G9a antibody, followed by protein A/G agarose beads. 
Subsequently, immunoprecipitates were analysed by western blot with anti-c-Myc 
antibody. The figure showed that G9a interact with Sharp-1 in both the proliferative 
myoblasts and differentiated myoblasts (Figure 3.9.7.). The result revealed that G9a 
and Sharp-1 interacted in the proliferating myoblasts and although their expression 









Figure 3.9.7 Endogenous G9a interacts with Sharp-1 in myoblasts.    
C2C12 cells were transfected with Myc-Sharp-1 and induced to differentiate for two 
days. Cell lysates were immunoprecipitated with anti-c-Myc agarose beads. Cell 
lysates and immunoprecipitates were analysed by western blot with anti-c Myc, anti-
G9a antibodies.  β-actin served as an internal control. 
 
 
3.9.8. Sharp-1 co-localises with di-methylated histone 3 lysine 9 
Since Sharp-1 associates with G9a, I examined if Sharp-1 co-localises with di-
methylated histone H3K9. C2C12 cells were immunostained with Sharp-1/DEC2 and 
H3K9me2 antibodies, followed by secondary fluorescence FITC and Texas-red 
antibodies. Nuclei were stained with DAPI. Fluorescence images showed that Sharp-1 
co-localised with di-methylated histone H3K9 in the nucleus of myoblasts (Figure 












Figure 3.9.8 Sharp-1 co-localises with di-methylated histone 3 lysine 9. 
Co-localisation of Sharp-1 and H3K9me2 was examined by immunofluorescence 
staining. C2C12 cells were immunostained with DEC2/ Sharp-1 antibody (green) and 
H3K9me2 antibody (red). Nuclei were stained with DAPI (blue). Images were 
merged and co-localised proteins were visualized by yellow fluorescence. 
 
 
3.10. Sharp-1 recruits G9a to block myogenic transcriptional activity  
3.10.1. G9a enhances Sharp-1-mediated inhibition of E-box-dependent 
transcriptional activity 
To examine the role of G9a in Sharp-1-dependent transcriptional repression, 
luciferase reporter assays were carried out. C2C12 cells were transfected with 6E-box 
driven firefly luciferase reporter (6E-TATA-Luc) with increasing amount of Sharp-1. 
Cell lysates were collected after 24 hours for luciferase activity analysis using Dual-
reporter luciferase assay system kit (Promega). The data showed that the 
transcriptional activity of the reporter was significantly inhibited with increasing 
amount of Sharp-1 (Figure 3.10.1.A). To examine the role of G9a, C2C12 cells were 
transfected with 6E-box driven firefly luciferase reporter (6E-TATA-Luc), Sharp-1 
and increasing amount of G9a. After 24 hours, renilla and luciferase activities were 
measured from the harvested cells. Sharp-1 transcriptional repression activity was 
enhanced with increasing amount of G9a (Figure 3.10.1.B). Thus, Sharp-1-mediated 
inhibition of transcriptional activity is augmented with methyltransferase G9a. In 
addition, a similar luciferase reporter assay was done to show that the transcriptional 
activity can be suppressed further by increasing both the transcriptional repressor 






Figure 3.10.1 G9a enhances Sharp-1 repression activity.  
C2C12 cells were transfected with 6E-box driven firefly luciferase reporter (6E-
TATA-Luc, 100 ng) with increasing amounts of Myc-Sharp-1 (ng)(A) or Myc-Sharp-
1 (50 ng) and with increasing amount of FLAG-G9a (ng) (B) or Sharp1 (25ng and 




activity was measured and normalised to renilla (2.5ng) luciferase. The mean value 
with standard deviation (error bar) was presented as percentage of the control (6E-
TATA-Luc only). P-values were calculated using Student's t-test and shown as * (p < 
0.05, significant). These experiments were performed at least twice. 
 
 
3.10.2. G9a enhances Sharp-1-mediated repression of MyoD transcriptional 
activity  
G9a enhances Sharp-1-mediated repression (Figure 3.10.1.) and we examined its 
impact on Sharp-1-dependent MyoD activation of myogenin promoter. To examine 
MyoD transcriptional activity, it is necessary to use a cell line such as C3H10T½ 
fibroblast cells which does not express endogenous MyoD. In reporter assay, 
exogenous expression of MyoD will bind to myogenin promoter-driven firefly 
luciferase reporter (pMyogLuc which contain myogenin promoter sequence) and drive 
the transcription of the luciferase reporter gene, thus giving a high luciferase activity. 
Hence, cells were transfected with pMyogLuc, MyoD, Myc-Sharp-1 and FLAG-G9a. 
After 24 hours, renilla and luciferase activities were measured. MyoD activated 
myogenin transcription was given a value of 100%, MyoD transcriptional activity was 
inhibited by Sharp-1 (48%) or G9a (45%) alone. In addition, this inhibitory effect was 
greater in the presence of both G9a and Sharp-1 (21%) (Figure 3.10.2.). Thus, G9a co-
operates with Sharp-1 in the transcriptional repression of MyoD activity and activation 



















Figure 3.10.2 G9a enhances Sharp1-mediated inhibition of MyoD transcriptional 
activity.  
C2C12 cells were transfected with myogenin promoter-drivenfirefly luciferase 
reporter (pMyogLuc), MyoD, Myc-Sharp1 and FLAG-G9a. 24 hours after 
transfection, luciferase activity was measured and normalised to Renilla luciferase. 
The mean value with standard deviation (error bar) was presented as percentage of 
control (80ng of MyogLuc with 50ng of MyoD). The assay was repeated at least twice 
with similar results. P-values were calculated using Student's t-test and shown as * (p 
< 0.05, significant). 
 
 
3.10.3. G9a∆ANK does not impact Sharp-1-dependent repression of the 
myogenin promoter and Sharp-1-bHLH-dependent repression is not increased 
by G9a 
To examine if the interaction of G9a and Sharp-1 is essential for repression of 
myogenin expression, C3H10T½ fibroblast cells were transfected with myogenin 
promoter-driven firefly luciferase reporter (pMyogLuc), MyoD, Myc-Sharp-1, Myc-




contrast to full length Sharp-1 which significantly inhibited MyoD activity, Sharp-
1bHLH repressed MyoD to a lesser extent and repression was not significantly 
increased in presence of G9a. Conversely, while G9a enhanced Sharp-1-dependent 
repression of MyoD, it did not have a major impact on repression by Sharp-1bHLH. 
These data support the notion Sharp-1-mediated repression of MyoD-transcriptional 













Figure 3.10.3 G9a∆ANK does not impact Sharp-1-dependent repression of the 
myogenin promoter and Sharp-1-bHLH-dependent repression is not increased 
by G9a.  
C2C12 cells were transfected with myogenin promoter-driven firefly luciferase 
reporter (pMyogLuc, 80 ng), MyoD, Myc-Sharp1, Myc-Sharp-1-bHLH, FLAG-G9a 
and FLAG-G9a∆ANK (50 ng). 24 hours after transfection, luciferase activity was 
measured and normalised to renilla (2.5 ng) luciferase. The mean value with standard 




The assay was performed at least two times with comparable results. P-values were 
calculated using Student's t-test and shown as * (p < 0.05, significant). 
 
 
3.11. Sharp-1 overexpression is associated with enhanced G9a-mediated 
H3K9me2 on myogenin promoter  
3.11.1. Sharp-1 enhances H3K9me2 on myogenin promoter 
Both the transcription factor Sharp-1 and transcriptional co-factor methyltransferase 
G9a inhibit skeletal muscle differentiation (Azmi et al., 2004, Figure 3.1.). In 
addition, Sharp-1 co-localises with both G9a and di-methylated histones H3K9 and 
interacts with methyltransferase G9a in the nucleus (Figure 3.9.). Since, G9a mediates 
repressive histone methylation marks, I investigated whether G9a-mediated 
H3K9me2 was apparent in presence of Sharp-1 on the myogenin promoter. The 
H3K9me2 levels on the myogenin promoter was assessed using ChIP assay.  C2C12 
cells were infected with pBabe (vector control) and pBabe-Sharp-1 retrovirus and 
expression of Sharp-1 was determined with DEC2 (Sharp-1) antibody (Figure 
3.11.1.A). Cells were cultured to proliferate in GM or DM for two days. Cells were 
harvested and subjected to ChIP assay with H3K9me2 antibody. Cells overexpressing 
Sharp-1 showed a similiar H3K9me2 pattern to that of cells overexpressing G9a 
(Figure 3.3.1.). Compared with control cells, H3K9me2 in Sharp-1-expressing cells 
was significantly higher on the myogenin promoter in both undifferentiated and 
differentiated cells (Figure 3.11.1.B).  
Moreover, in the control cells, an increase of H3K9K14ac level on myogenin 
promoter correlated with an increase in the expression of muscle genes required 
during cells differentiation. In contrast, the H3K9K14ac level was reduced in Sharp-
1-expressing cells (Figure 3.11.1.C). Thus, elevated Sharp-1 expression enhances 
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H3K9me2 and reduces H3K9K14ac level at the myogenic promoter which correlates 













Figure 3.11.1 Overexpression of Sharp-1 alters H3K9me2 and H3K9K14ac levels 
on myogenin promoter. 
Sharp-1 expression in Phoenix cells was analysed by western blot using DEC2 
(Sharp-1) antibody. β-actin was used as a loading control (A). C2C12 cells were 
infected with pBabe (vector control) or pBabe-Sharp-1 retrovirus. Transfected cells 
were selected with puromycin and induced to proliferate (day 0) or differentiate (day 
2). Cells were fixed and subjected to ChIP analysis using H3K9me2 antibody (B) or 
H3K9K14ac antibody (C). Immunoprecipitated chromatin was analysed by Q-PCR 
using primers for myogenin promoter and normalised to internal control ß-actin gene.  
Values are presented as means with standard deviation (error bar). Results are 
representative of at least two independent ChIP experiments. P-values were calculated 






3.12. Sharp-1 enhances G9a-mediated methylation of MyoD  
3.12.1. Sharp-1 associates with G9a to methylate MyoD at lysine K104 
Earlier it was shown that MyoD(K104R) is more effective that wild-type MyoD in 
rescuing the differentiation defect which indicates that methylation of MyoD at 
Lysine 104 was crucial in G9a-mediated inhibition of myogenic differentiation. 
Hence, besides investigating that Sharp-1 associates with G9a-mediated methylation 
of H3K9 on the myogenin promoter, it is also necessary to investigate if methylation 
of MyoD also occurs in Sharp-1-expressing cells. C3H10T½ mouse fibroblast cells 
were used to further examine the role of Sharp-1 in association with G9a in 
myogenesis. C3H10T½ mouse fibroblast cells do not express MyoD and can be 
converted to myoblast-like cells upon transfection with MyoD (Salvatori et al., 1995). 
Cells were transfected with FLAG-G9a, Myc-Sharp-1, MyoD and MyoD(K104R) 
mutant. Cell lysates were immunoprecipitated with MyoD and subjected to western 
blot analysis. The expression of FLAG-G9a, MyoD, MyoD(K104R) mutant, Myc-
Sharp-1 was determined. In the presence of Sharp-1, higher levels of methylated 
MyoD were apparent. However, G9a was not able to methylate MyoD(K104R) 
mutant in the absence or presence of Sharp-1 (Figure 3.12.1.). These studies suggest 
that Sharp-1, G9a and MyoD may co-exist in protein complex and Sharp-1 enhances 










Figure 3.12.1 Sharp-1 enhances MyoD methylation at lysine K104. 
C3H10T½ cells were transfected with MyoD, MyoD(K104R), FLAG-G9a and Myc-
Sharp-1 and immunoprecipitated with MyoD antibody. The expression of G9a, MyoD 
and MyoD(K104R) and Sharp-1 in cell lysates was analysed by western blot with anti-
FLAG antibody, anti-c-Myc antibody, anti-MyoD antibody. The MyoD 
immunoprecipitates were analysed by western blot with methyl lysine (Me Lys) 
antibodies.         
 
 
3.12.2. Sharp-1 represses MyoD transcriptional activity to a greater extent than 
MyoD(K104R)  
Sharp-1 is known to block MyoD transcriptional activity partially through its bHLH 
domain but this does not appear to be dependent on the recruitment of HDAC1 
(Fujimoto et al., 2007). In the presence of Sharp-1, both increased MyoD methylation 
at K104 and a higher level of H3K9me2 was observed. To examine the impact of 
Sharp-1 on the transcriptional activity of MyoD and MyoD(K104R), a luciferase 
reporter assay was performed. C3H10T½ fibroblast cells were transfected with 
pMyogLuc, Sharp-1, MyoD and MyoD(K104R) and cultured in differentiating 
medium. After 24 hours, cell lysates were collected and luciferase and renilla 
activities were measured. Sharp-1 repressed both MyoD and MyoD(K104R) 
transcriptional activity but the repression of MyoD was greater compared to the 
repression of MyoD(K104R) (Figure 3.12.2.). This indicates that Sharp-1-mediated 















Figure 3.12.2 Sharp-1 represses MyoD transcriptional activity to a greater extent 
than MyoD(K104R). 
C3H10T½ cells were transfected with myogenin promoter-driven firefly luciferase 
reporter (pMyogLuc)(80 ng), MyoD, MyoD(K104R) and Myc-Sharp-1 (50 ng). Cells 
were cultured in differentiation medium. After 24 hours, luciferase activity was 
measured and normalised to renilla luciferase (2.5 ng). The mean value with standard 
deviation (error bar) was presented as percentage of control (pMyogLuc and MyoD). 
The assay was repeated at least twice. P-values were obtained using Student's t-test 
and shown as * (p < 0.05), *** (p<0.001). 
 
 
3.13. BIX-01294 rescues Sharp-1-mediated inhibition of myogenesis 
3.13.1. Inhibition of G9a activity reverses Sharp-1-mediated repression 
G9a enhanced Sharp-1-mediated repression of E-box-dependent transcriptional 
activity. To confirm that this Sharp-1-mediated repression was associated with G9a 
methyltransferase activity, we performed a similar luciferase assay with the G9a 
inhibitor, BIX-01294. C2C12 cells were transfected with 6E-box driven firefly 




BIX-01294, Sharp-1 transcriptional repression was ameliorated (Figure 3.13.1.A). 
Moreover, treatment with BIX-01294 significantly improves MyoD transcriptional 
activity that was repressed by Sharp-1 (Figure 3.13.1.B) confirming that G9a 
methyltransferase activity is involved in Sharp-1-mediated repression of MyoD 
activity. C3H10T½ fibroblast cells were transfected with myogenin promoter-driven 
firefly luciferase reporter (pMyogLuc), MyoD,  Myc-Sharp-1 and incubated with 2.5 






Figure 3.13.1  BIX-01294 rescues Sharp-1-mediated inhibition of transcriptional 
activity. 
C2C12 cells were transfected with 6E-box driven firefly luciferase reporter (6E-
TATA-Luc, 100 ng), Myc-Sharp-1 and in the presence or absence of 2.5 µM BIX-
01294 (a G9a inhibitor)(A). C3H10T½ cells were transfected with myogenin 
promoter-driven firefly luciferase reporter (pMyogLuc, 80 ng ), MyoD (50 ng), Myc-
Sharp-1 (50 ng) and incubated with 2.5 µM of BIX-01294 (B). 24 hours after 




luciferase. The mean value with standard deviation (error bar) was presented as 
percentage of the control (6E-TATA-Luc or pMyogLuc). Values are representative of 
at least two independent experiments. P-values were calculated using Student's t-test 
and shown as * (p < 0.05, significant) and ** (p < 0.01, very significant) 
 
 
3.13.2. BIX-01294 reverses Sharp-1-mediated H3K9me2 on myogenin promoter  
BIX-01294 blocks Sharp-1 repression of MyoD activity. To examine its impact on 
Sharp-1-induced H3K9me2 on myogenin promoter, ChIP assays were carried out in 
Sharp-1-overexpressing cells without and with BIX-01294 treatment. C2C12 cells 
were infected with pBabe-Sharp-1 retrovirus, and Sharp-1 expression in cells was 
confirmed by western blot analysis (Figure 3.13.2.A). One set of cells expressing 
Sharp-1 was treated with 2.5 µM of BIX-01294 while the other set was treated with 
same volume of DMSO (control). Cells, cultured in GM and then induced to 
differentiate in DM for two days, were subjected to ChIP assays with H3K9me2 
antibody. Both DMSO-treated and BIX-01294-treated cells showed a decrease in the 
H3K9me2 on myogenin promoter as cell differentiated. However, compared to 
DMSO-treated Sharp-1 expressing cells, treatment with BIX-01294 resulted in lower 
H3K9me2 on myogenin promoter (Figure 3.13.2.B). Therefore, the G9a inhibitor 
BIX-01294 inhibits Sharp-1-mediated repression of MyoD activity and reduces 




















Figure 3.13.2  BIX-01294 rescues Sharp-1-induced H3K9me2 on myogenin 
promoter.  
Sharp-1 expression in Phoenix cells was determined by western blot analysis. β-actin 
was used as a loading control (A). C2C12 cells were infected with pBabe-Sharp-1 
retrovirus. Cells were treated with DMSO (control) or 2.5 µM of BIX-01294 and 
induced to differentiate for two days. Cell lysates were subjected to ChIP analysis 
using H3K9me2 antibody. DNA was analysed by Q-PCR using primers for the 
myogenin promoter and the values obtained were normalised to β-actin. Relative 
DNA level was determined and presented as means with standard deviation  (error 
bar). Similar results were observed in at least two separate experiments. p-values were 
calculated using Student's t-test and indicated as ** (p < 0.01, very significant) (B). 
 
 
3.13.3. BIX-01294 reduces Sharp-1-mediated methylation of MyoD  
Sharp-1 associates with G9a and mediates H3K9me2 on myogenin promoter. 
Moreover, Sharp-1 represses MyoD transcriptional activity during the inhibition of 




G9a inhibit myogenic transcription both by di-methylation of H3K9 on the myogenin 
promoter and methylation of MyoD protein (Ling et al., 2012, Figure 3.3.1.), the role 
of Sharp-1 in MyoD methylation was analysed by western blot.  
Cells were transfected with MyoD and Sharp-1 and left untreated or treated with BIX-
01294. Lysates were analysed for expression of endogenous G9a, MyoD and Myc-
Sharp-1. Cell lysates were then immunoprecipitated with MyoD and analysed by 
western blot to determine MyoD methylation and its association with G9a in the 
presence of Sharp-1. G9a association with MyoD was increased and correspondingly 
MyoD methylation. Sharp-1-mediated increased in methylation of MyoD could be 
blocked by BIX-01294 (Figure 3.13.3.). Thus, Sharp-1 promotes G9a association with 










Figure 3.13.3 BIX-01294 blocks Sharp-1-mediated methylation of MyoD.  
C2C12 cells were transfected with MyoD and/or Myc-Sharp-1. Transfected cells were 
treated with DMSO (control) or 2.5 µM BIX-01294. Cell lysates were analysed by 
western blot with anti-G9a, anti-MyoD or anti-c-Myc antibody. β-actin was used as a 
internal control. The MyoD immunoprecipitates were analysed by western blot with 




3.13.4. Inhibition of G9a activity rescues Sharp-1-mediated block of 
differentiation  
To determine the role of G9a in Sharp-1-dependent block of myogenesis, C2C12 cells 
overexpressing pBabe and pBabe-Sharp-1 were treated with DMSO (control) or with 
2.5 µM of BIX-01294 and cultured for differentiation assays. Cells were fixed and 
immunostained with MHC primary antibody, followed by Texas-red secondary 
antibody. Sharp-1 expressing cells showed lesser number of MHC-positive myotubes 
formed as compared to control cells and BIX-01294-treated Sharp-1 expressing cells 
(Figure 3.13.4.A). Therefore, G9a methyltransferase activity is involved in Sharp-1-
mediated inhibition of myotube formation and thus, the differentiation defect can be 
rescued with BIX-01294. Calculation of the myogenic index revealed a significant 
recovery of MHC-positive myotubes in BIX-01294 treated cells overexpressing 
Sharp-1 (Figure 3.13.4.B). Cell lysates were collected and analysed by western blot 
for myogenic differentiation markers, myogenin and troponin T. β-actin was used as 
an internal control. The results showed that inhibition of G9a activity restored 

































Figure 3.13.4 BIX-01294 blocks Sharp-1-mediated inhibition of differentiation 
and expression of muscle-specific genes.  
 pBabe- (vector control) or pBabe-Sharp-1-expressing cells were treated with DMSO 
(control) or 2.5 µM BIX-01294 and induced to differentiate for two days. Myotube 
formation was assessed by immunofluorescence staining with anti-myosin heavy 




merged and captured using fluorescence microscope with 20x magnification (A). The 
extent of cell differentiation was determined by myogenic index. The mean value with 
standard deviation (error bar) obtained was expressed as percentage of the control 
(pBabe). P-values were calculated using Student's t-test and indicated as ** (p < 0.01, 
highly significant) (B). Day 0 and 2 cells lysates were analysed by western blot for 
myogenic marker myogenin and troponin T. β-actin was loaded as an internal control 
(C). These experiments were conducted at least two times with similar results.  
 
 
3.14. siRNA knockdown of G9a rescues Sharp-1-mediated inhibition of 
myogenesis   
3.14.1. siRNA-mediated knockdown of G9a rescues Sharp-1-induced inhibition of 
differentiation 
A higher concentration of BIX-01294 has been reported to inhibit other 
methyltransferase such as GLP (Kubicek et al, 2007, Link et al., 2009). To ascertain if 
the differentiation defects induced by Sharp-1 was mediated through G9a, 
differentiation assays were performed with siRNA knockdown of G9a (siG9a). Sharp-
1-overexpressing myoblast cells were transfected with siRNA or siG9a. Cells were 
cultured in GM and then DM to induce cellular differentiation for two days. Cell 
lysates were collected and subjected to western blot analysis for G9a expression. 
Western blot analysis showed that both G9a expression levels were clearly reduced 
with G9a knockdown (Figure 3.14.1.A). Upper band and lower band correspond to the 
long isoform and short isoform of G9a, respectively. Both control and siG9a cells 
were differentiated, and analysed for MHC-positive myotubes by immunofluorescence 
with anti-MHC antibody. G9a knockdown resulted an increased in the number of 
MHC-positive myotubes in Sharp-1-expressing cells (Figure 3.14.1.B). Thus, Sharp-1-
mediated repression of myogenesis can be overcome by reducing G9a expression 
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during myoblast differentiation. This data further confirms that Sharp-1-represses 
myogenic differentiation through association with G9a. Myogenic index was 
determined to quantify the extent of recovery. A significant 7-fold increase in MHC-






Figure 3.14.1 siRNA-mediated knockdown of G9a rescues Sharp-1-induced 
inhibition of differentiation. 
pBabe-Sharp-1-expressing C2C12 cells were transfected with scrambled siRNA 
(control) or siRNA targeting G9a (siG9a). Cell lysates were analysed by western blot 
for G9a protein expression (A). Cells were induced to differentiate for two days and 
examined for myogeic differentiation. Cells were immunostained with anti-MHC 
antibody (red) and nuclei were stained with DAPI (blue). The images were merged 
and captured under a fluorescence microscope with 20x magnification (B). Myogenic 
index of pBabe-Sharp1 with scrambled siRNA or siG9a were determined as ratio of 
MHC-positive nuclei over total nuclei (at least 600 nuclei scored in each field). 
Values were shown as means with standard deviation (error bar). P-values were 
calculated using Student's t-test and indicated as ** (p < 0.01, very  significant) (C). 
The assay was repeated twice with similar results observed.   
 
 
3.14.2. Inhibition of G9a expression rescues Sharp-1-induced inhibition of MyoD 
target genes  
The reduction of G9a expression in Sharp-1 expressing cells restored differentiation, 
the expression of myogenic markers was examined. Lysates from siRNA and siG9a 
cells were subjected to western blot analysis. In Sharp-1 expressing cells with G9a 
knockdown, the expression of both myogenic differentiation markers, myogenin and 
troponin T was increased (Figure 3.14.2). Together, data suggested that Sharp-1 













Figure 3.14.2 Inhibition of G9a expression rescues Sharp-1-induced inhibition of 
MyoD target genes.  
pBabe-Sharp-1-expressing C2C12 cells were transfected with scrambled siRNA 
(control) or siRNA targeting G9a (siG9a). Cell lysates were analysed by western blot 




3.15. Re-expression of MyoD rescues Sharp-1-mediated inhibition of myogenesis   
3.15.1. MyoD(K104R) exhibits increased activity in rescuing Sharp-1-mediated 
inhibition of differentiation 
To examine whether MyoD(K104R) is indeed refractory to inhibition, C2C12 cells 
expressing Sharp-1 were transfected with pCS2 control vector, MyoD or 
MyoD(K104R). Cells were cultured in GM, followed by DM to induce differentiation 
for three days. The expression of MyoD and MyoD(K104R) in pBabe-Sharp-1-
expressing cells were determined by western blot (Figure 3.15.1.A). The cells were 
differentiated and stained with MHC antibody. Consistent with the previous data, 
MyoD(K104R) was more effective than MyoD in rescuing myogenic differentiation 
in Sharp-1-overexpressing cells (Figure 3.15.1.B). Thus, re-expressing MyoD rescues 
myotube formation in Sharp-1-expressing cells and the effect is enhanced with 




mediated recruitment of G9a. Myogenic index in Sharp-1 expressing cells rescued by 
MyoD and MyoD(K104R) was assessed. Rescue of MHC-positive myotubes in 
Sharp-1 expressing cells was significantly better with MyoD(K104R) compared with 
























Figure 3.15.1 MyoD(K104R) is more effective than MyoD at restoration of the 
myotube formation in Sharp-1 overexpressing cells. 
Sharp-1-expressing cells were transfected with pCS2 (control), MyoD and 
MyoD(K104R) and induced to differentiate for three days. Cell lysates were analysed 
by western blot for the expression MyoD, MyoD(K104R) mutant. β-actin was used as 
a loading control (A). Myogenic differentiation was assessed by immunofluorescence 
staining with anti-MHC antibody (red). Nuclei were counterstained with DAPI (blue). 
Images were microscope with a 10x magnification (B). The extent of the myotube 
formation was evaluated with myogenic index. The mean value obtained was 
presented as a percentage of control (C2C12 cells transfected with pCS2 only) with 
standard deviation (error bar). P-values were calculated using Student’s t-test (* 
p<0.05, significant, ** p<0.01, highly significant) (C). Similar results were observed 
from at least two independent experiments. 
 
 
3.15.2. Re-expression of MyoD(K104R) results in higher troponin T expression in 
Sharp-1-overexpressing cells 
To examine the muscle protein expression, cell lysates were collected and analysed 
for the expression of muscle differentiation genes. Consistent with a block in 
differentiation, Sharp-1 expressing cells showed less troponin T expression than 
control cells. Consistent with the MHC-positive cells and myogenic index, earlier and 
increased troponin T expression was seen in cells transfected with MyoD(K104R), 
compared to MyoD (Figure 3.15.2). Therefore, increasing the expression of MyoD 
and MyoD(K104R) restore expression of muscle differentiation genes and overcome 
the differentiation defects mediated by Sharp-1. Since MyoD(K104R) is not 
methylated and its activity not inhibited by Sharp-1 associated with G9a, the rescue of 













Figure 3.15.2 Re-expression of MyoD(K104R) results in higher troponin T 
expression in Sharp-1-overexpressing cells. 
Sharp-1-expressing cells were transfected with pCS2 (control), MyoD and 
MyoD(K104R) and induced to differentiate for three days. Cell lysates were collected 
from cells at day 0, 1, 3 and analysed for terminal differentiation marker troponin T. 
β-actin was used as a loading control. 
 
 
3.15.3. MyoD or MyoD(K104R) do not alter H3K9me2 on myogenin promoter 
during differentiation  
During the inhibition of myogenic differentiation, besides methylation of MyoD 
activity, H3K9me2 on myogenin promoter can also repress transcription of muscle 
genes. H3K9me2 on myogenin promoter was assessed by ChIP assay in Sharp-
1expressing cells that were transfected with MyoD and MyoD(K104R). Cell lysates 
were immunoprecipitated with H3K9me2 antibody and amplified with primers 
specific to myogenin promoter. In Sharp-1 overexpressing cells, re-expression of 
MyoD and MyoD(K104R) resulted in similar levels of H3K9me2 levels on myogenin 
promoter (Figure 3.15.3). This indicates the methylation of MyoD plays a greater role 














Figure 3.15.3 Re-expression of MyoD or MyoD(K104R) does not alter H3K9me2 
on myogenin promoter in Sharp-1-expressing cells. 
Sharp-1-expressing C2C12 cells were transfected with MyoD and MyoD(K104R) 
mutant and induced to differentiate for two days. Cell lysates were used for ChIP 
analysis to determine the H3K9me2 on the myogenin promoter. Chromatin was 
analysed by QPCR using primers for the myogenin promoter and β-actin gene (an 
internal control). Values obtained were plotted as means with standard deviation 
































4. Discussion     
Skeletal muscle cell differentiation in embryonic development and post-natal muscle 
regeneration is positively regulated by MRFs as well as negatively controlled by 
repressors such as Sharp-1. The inhibitory activity of Sharp-1 occurs through several 
mechanisms. One way is through the interaction with MyoD and E-protein, thus 
preventing formation of MyoD-E protein complexes from activating muscle genes. 
However, the mechanisms of Sharp-1 in myogenesis are not well defined. In this 
study, I have identified lysine methyltransferase G9a as a novel transcriptional co-
repressor that directly associates with Sharp-1, and is critical for Sharp-1-mediated 
repression of MyoD activity and muscle differentiation. Similar to Sharp-1, G9a itself 
has an inhibitory role in skeletal myogenesis. I demonstrated that both Sharp-1 and 
G9a expression decline as cells undergo terminal differentiation. In addition, 
overexpression of Sharp-1 or G9a alone blocks muscle differentiation. These results 
are consistent with a previous study which demonstrated that Sharp-1 expression 
downregulated during differentiation and the expression of muscle genes required for 
myoblast differentiation are transcriptionally repressed in Sharp-1-expressing cells 
(Azmi et al., 2004).  
Studies thus far have not shown any role of G9a in muscle cells. Hence, for the first 
time, I found that G9a inhibit muscle differentiation and its repression is dependent 
upon its lysine methyltransferase activity, conferred by the SET domain. Deletion of 
the catalytic domain in G9a abrogates inhibition of myogenic differentiation. A 
methyltransferase inhibitor BIX-01294 was shown to selectively target G9a reduce 
H3K9me2 levels in mammalian cells at low micromolar concentration (Kubicek et al., 
2007, Chang et al., 2009). Notably, inhibition of G9a activity with BIX-01294 
reduces G9a-mediated transcriptional repression of muscle differentiation genes, 
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confirming that the methyltransferase activity of G9a is required for inhibition of 
muscle differentiation program. Although myogenin expression was induced after 
long exposure with BIX-01294 in myoblasts, no myotubes developed which implies 
the presence of other inhibitors that co-function with G9a to prevent myoblast 
differentiation. Although a low concentration of BIX-0129 was used, the specificity 
may still be an issue since it can also inhibit GLP (Chang et al., 2009, Shinkai et al., 
2011). Hence, countering this specificity problem, a more specific drug UNC0638 or 
siRNA-mediated knockdown of G9a are alternatively used in the assay with the same 
results obtained (data not shown here but can be found in Ling et al., 2012).   
Apart from epigenetic modulation of histones, G9a is also capable of binding to and 
methylating MyoD at K104 which attenuates its transcriptional activity (data not 
shown here but can be found in Ling et al., 2012). Consistent with this finding, results 
showed that re-expression of MyoD(K104R) which is incapable of being methylated 
by G9a, rescues the differentiation block imposed by G9a better than wild type MyoD.  
Besides repression of muscle-specific gene expression, I present evidence that G9a 
also inhibits p21 expression and facilitates cell cycle progression both in proliferating 
and differentiating myoblasts. Many reports have previously demonstrated that G9a 
downregulates p21 gene in non-muscle cells, resulting in increased expression of S-
phase genes and promoting high mitotic index (Gyory et al., 2004, Nishio and Walsh, 
2004, Kim et al., 2008). In myogenesis, however, the upregulation of p21 by MyoD is 
necessary to promote permanent cell cycle exit prior to myoblast differentiation (Guo 
et al., 1995, Hawke et al., 2003). Hence, I hypothesize that G9a mediates H3K9me2 
on p21 promoter restricting its gene expression and causing a delay in cell cycle exit. 
Thus, myoblasts that fail to exit the cell cycle will resist terminal differentiation. This 
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is another possible mechanism by which G9a may control cell-cycle regulators and 
lead to an impairment of muscle cell differentiation.  
I also showed that overexpression of Sharp-1 in myoblasts results in differentiation 
defects similar to those observed with overexpression of G9a. Sharp-1 increases 
H3K9me2 and decreases H3K9K14ac levels on myogenin promoter, as well as 
increases methylation of MyoD. These findings suggest that H3K9me2 plays a role in 
Sharp-1-mediated silencing of gene expression. G9a is a transcriptional co-repressor 
that is responsible for H3K9me2 but it does not contain a DNA-binding sequence and 
needs to be recruited by a transcription factor. Following, it was discovered that the 
physical interaction between Sharp-1 and G9a is required in Sharp-1-mediated 
repression. The protein interaction studies establish that G9a through its ankyrin 
domain interacts directly with Sharp-1, via its C-terminus spanning amino acids 173 
to 265. The G9a interaction with Sharp-1 is important as the repressive effect of 
Sharp-1 on MyoD transcriptional activity was enhanced in the presence of G9a but 
not G9a∆ANK mutant which cannot associate with Sharp-1. In addition to their direct 
association, Sharp-1-inhibitory mechanisms also require G9a methyltransferase 
activity. This observation is clearly supported by experiments showing that the 
methyltransferase inhibitor BIX-01294 is able to overcome Sharp-1-mediated 
repression of MyoD transcriptional activity and muscle gene expression. Moreoever, 
siRNA-induced knockdown of G9a expression or inhibition of G9a activity by BIX-
01294 partially reverses Sharp-1-mediated inhibitory effect on muscle differentiation. 
Furthermore, exogenous expression of MyoD(K104R) rescues Sharp-1-mediated 
differentiation defects better than wild type MyoD. Collectively, my data 
demonstrates that Sharp-1-mediated inhibition of myogenesis is at least partially 
dependent on recruitment of G9a at the muscle promoters and MyoD. The mechanism 
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Apart from my research study in skeletal muscle, many previous works on non-
muscle cell type have established G9a as an important epigenetic regulator where it 
limits the access of regulatory proteins to DNA, thus posing serious restraints to 
biological processes such as replication and transcription. A disruption of the balance 
in the biological processes can cause several major pathologies including syndromes 
involving chromosomal instabilities, and mental retardation. For example, a report 
demonstrated that the maintenance of CpG methylation in Prader Willi Syndrome 




requires G9a-mediated H3K9 methylation (Xin et al., 2003). Another report revealed 
that G9a has a crucial role in drug addiction, where they showed that repeated cocaine 
administration reduced global levels of H3K9 dimethylation and promoted cocaine 
preference in mice (Maze et al., 2010). Lee and his group found that G9a functions 
both as a co-repressor for specific transcription factors and co-activators for nuclear 
receptors, co-operating synergistically with gene expression punctually (Lee et al., 
2006). Work from Shinkai group showed that G9a-deficient embryos die during early 
development with drastic loss of H3K9me levels in the euchromatic regions and 
increased cell death. Their findings suggest that G9a is required for the efficient 
repression of developmentally regulated genes during embryogenesis (Tachibana et 
al., 2008).  
For the past years, researchers also study the mechanism of G9a in the carcinogenesis 
and development of human malignant tumor. For example, recent studies provided 
insight into how RelB recruits G9a to initiate gene silencing, resulting in phenotype 
associated with severe systemic inflammation in human (Chen et al., 2009). A 
researcher showed that G9a also plays an important role in the hypoxia-induced 
H3K9me2, which would inhibit the expression of several genes that would likely lead 
to solid tumor progression (Chen et al., 2006). In human breast cancer, G9a interacts 
with Snail and is critical for Snail-mediated E-cadherin repression (Dong et al., 2012). 
In addition, histone modifications by G9a are involved in regulating centrosome 
duplication presumably through chromatin structure rather than through affecting 
gene expression in cancer cells (Kondo et al., 2008). Another study suggests that G9a 
is a potential inhibitory target for cancer treatment where their data revealed a new 
methylation site within p53 mediated by the methylases G9a (Huang et al., 2010).  
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Many data confirmed the association between the presence of G9a and cancer, 
however, there are no reports on G9a in myopathies. Although there have been no 
reports on G9a role in myogenesis and myopathy, other methyltransferase such as 
Suv39h1/KMT1A has been shown to impair MyoD function and arrest myogenic 
differentiation in alveolar rabdomyosarcoma (Lee et al., 2011). Another report 
revealed that SUV39H1–mediated H3K9 tri-methylation at tandem repeat sequence 
D4Z4 seen in normal cells is lost in Facioscapulohumeral dystrophy, an autosomal 
dominant muscular dystrophy (Zeng et al., 2009). However, it is still unclear how 
transcriptional repressor Suv39H1 is associated with MyoD and the molecular 
mechanism of the methyltransferase that caused the blockade of differentiation 
remains to be determined. This research work therefore highlights the possibility of 
another methyltransferase and a mechanism contributing to the failure of myogenic 
differentiation, paving the way to new therapeutic options.  
As for Sharp-1, it has been documented to be involved in the regulation of 
differentiation and growth of several cell types beside skeletal muscle. One study 
found that Sharp-1 plays a role in terminal neuronal differentiation (Rossner et al., 
1997) while another study demonstrated that Dec2/Sharp-1 regulates TH2 lineage 
commitment and cell differentiation (Yang et al., 2009a). Sharp-1 blocks adipocyte 
differentiation by interacting with and inhibiting transcriptional activity of both 
CEBP/α and CEBP/β (Gulbagci et al., 2009). A genetic study found that a mutation in 
Sharp-1 gene may affect sleep time in mice (He et al., 2009). Researchers have also 
explored the role of Sharp-1 in tumorigenesis and cancer progression. It has been 
shown that Sharp-1 suppresses p53-mediated apoptotic activities and mediates 
cellular response to DNA damage (Liu et al., 2010). Clinical data revealed that Sharp-
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1 suppresses breast cancer metastasis through degradation of hypoxia-inducible factors 
(Montagner et al., 2012).  
Concerning muscle development, it has been documented that Sharp-1 interacts with 
and inhibits MyoD transcriptional activity, resulting in myogenic differentiation 
defects (Azmi et al., 2004). Similar to these findings, it was found that Sharp-1 is 
highly expressed in inclusion body myositis, an inflammatory muscle disease 
(Morosetti et al., 2006). While many studies provide strong evidence that Sharp-1 
expression correlated with pathologies, however its repressive mechanisms in skeletal 
myogenesis are not well defined. Therefore, the study here has provided a platform 
for understanding the molecular mechanisms of Sharp-1 in inhibiting myogenesis and 
its possible link with myopathies. Observations from several pathological studies, 
together with findings reported here raise the possibility of a therapeutic potential of 

























Conclusion and future studies 
This research study elucidates the mechanism by which Sharp-1 mediates 
transcriptional silencing of muscle genes in myoblasts via its association with the co-
factor G9a. This information is useful towards understanding the development and 
regeneration process in skeletal muscle. However, there are some unknowns in the 
present study and require further investigation.  
Besides repressing myogenic differentiation genes, G9a participates in the 
downregulation of p21 expression which contributes to maintenance of myoblast 
proliferation and probably results in delaying cell differentiation. At this stage, it is 
not known if G9a is involved in regulating other cell cycle genes and raises the 
question of whether G9a has any important role in controlling the cell cycle exit and 
consequently differentiation as well as possibly regulating cellular quiescence. As 
such, the function of G9a in cell cycle progression remains to be determined. In 
addition, G9a and GLP protein complexes mediate H3K9 methylation and DNA 
methylation to silence gene transcription (Tachibana et al., 2008, Collins et al., 2010) 
which raises the possibility of the role of GLP and its co-operation with G9a in the 
regulation of myogenesis. Furthermore, it has been shown that G9a indirectly 
methylates DNA through recruitment of Dnmtase (Litman et al., 2008) and G9a 
knockout cells demonstrates a significant reduction of DNA methylation (Litman et 
al., 2008, Xin et al., 2003, Esteve et al., 2006, Dong et al., 2008). Thus, it will be 
interesting to find out if Dnmtase are also involved in Sharp-1-mediated block of 
muscle cell differentiation and development. Hence, further investigations on the 
mechanism of Sharp-1 and G9a in regulating myogenesis are necessary as many G9a-
related questions remain.  
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More in-depth work will involve analysing the role of G9a in muscle development 
and regeneration in vivo, as well as identification of target genes and determining if its 
expression or activity is perturbed in muscle disorders such as muscular dystrophies. 
Muscle regeneration depends on the activation and proliferation of satellite cells. It is 
not known if G9a is also involved in the activation of satellite cells and muscle 
regeneration since it is likely to be involved in the proliferation of muscle cells. Hence, 
further in-depth studies are necessary to determine if G9a is involved in skeletal 
muscle regeneration.  
Together, this research work and future work will provide new insights into Sharp-1-
dependent regulation of myogenesis and identify epigenetic mechanisms which could 
be targeted in myopathies characterized by elevated Sharp-1 levels. These will be 
useful towards the development of new therapeutic strategies in the treatment of the 













Table I. Primers for RT-PCR. 
 















TTG CGCCGG 65 28 
MyoD GCCCGCGCTCCAACTGCTCTGAT 
CCTACGGTGGTGCGCC
CTCTGC 58 25 
Myogenin GGGCCCCTGGAAGAAAAG 
AGGAGGCGCTGTGGGA
GTT 58 25 
36B4 CAGCTCTGGAGAAACTGCTG 
GTGTACTCAGTCTCCAC




TABLE II. Primers for Q-PCR. 
 


































TABLE III. Primers for siRNA. 
 
Smart pool siRNA sequences sequence matching sequence  (in human) 
Non-targeting siRNA -1 UGGUUUACAUGUCGACUAA 
 
Non-targeting siRNA -2 UGGUUUACAUGUUGUGUGA 
 
Non-targeting siRNA -3 UGGUUUACAUGUUUUCUGA 
 


















TABLE IV.  Primers for cloning Sharp-1 mutants. 
  
Gene Forward primer Reverse primer TM (°C) 
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